EP2207591A2 - Systèmes et méthodes de traitement d'états pathologiques associés au système nerveux central et destinés à améliorer les fonctions cognitives - Google Patents

Systèmes et méthodes de traitement d'états pathologiques associés au système nerveux central et destinés à améliorer les fonctions cognitives

Info

Publication number
EP2207591A2
EP2207591A2 EP08835645A EP08835645A EP2207591A2 EP 2207591 A2 EP2207591 A2 EP 2207591A2 EP 08835645 A EP08835645 A EP 08835645A EP 08835645 A EP08835645 A EP 08835645A EP 2207591 A2 EP2207591 A2 EP 2207591A2
Authority
EP
European Patent Office
Prior art keywords
brain
cognitive
stimulator
stimulation
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP08835645A
Other languages
German (de)
English (en)
Inventor
Jonathan Bentwich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neuronix Ltd
Original Assignee
Neuronix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/153,037 external-priority patent/US8498708B2/en
Application filed by Neuronix Ltd filed Critical Neuronix Ltd
Publication of EP2207591A2 publication Critical patent/EP2207591A2/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
    • A61N1/3606—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
    • A61N1/36082—Cognitive or psychiatric applications, e.g. dementia or Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/36014—External stimulators, e.g. with patch electrodes
    • A61N1/36025—External stimulators, e.g. with patch electrodes for treating a mental or cerebral condition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
    • A61N1/0526—Head electrodes
    • A61N1/0529—Electrodes for brain stimulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
    • A61N1/0526—Head electrodes
    • A61N1/0546—Nasal electrodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
    • A61N1/0526—Head electrodes
    • A61N1/0548—Oral electrodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/326—Applying electric currents by contact electrodes alternating or intermittent currents for promoting growth of cells, e.g. bone cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N2/00—Magnetotherapy
    • A61N2/002—Magnetotherapy in combination with another treatment

Definitions

  • the present invention relates to systems and methods for diagnosing and treating medical conditions associated with the neural system, and for enhancing cognitive functions in individuals. BRIEF SUMMARY OF THE INVENTION
  • the present invention provides methods and systems configured to identify and treat various medical conditions associated with the neural system.
  • the present invention also provides systems and devices for enhancing cognitive functions in individuals.
  • FIG. 1 is a schematic block-diagram of an integrative neuro-cognitive system according to an exemplary embodiment of the present invention
  • FIG. 2 is a schematic block-diagram of the NEURODIAGNOSTICS MODULE of the system of FIG. 1 ;
  • FIG. 3 is a schematic block-diagram of the REGIONS OF INTEREST COMPUTATIONAL MODULE of the system of FIG. 1 ;
  • FIG. 4 is a schematic block-diagram of the BRAIN TRAIT COMPUTATION MODULE of the system of FIG. 1 ;
  • FIG. 5 is a schematic block-diagram of the TREATMENT MODULE of the system of FIG. 1 ;
  • FIG. 6 is a schematic block-diagram of the STIMULATION MODULE of the system of FIG. 1 ;
  • FIG. 7 is a schematic block-diagram of the BRAIN STIMULATOR of the STIMULATION MODULE of FIG. 6;
  • FIG. 8 is another schematic representation of the BRAIN STIMULATOR of the STIMULATION MODULE of FIG. 6; [00014] FIG. 9 illustrates the system for Embodiment A;
  • FIG. 10 illustrates the system for Embodiment B
  • FIG. 1 1 illustrates the system for Embodiment C
  • FIG. 12 is a computer application block diagram
  • FIG. 13 is the END Block Diagram
  • FIG. 14 is the ISAT Inter-Subject Across Time Block Diagram
  • FIG. 15 is the NDA Normative Data Analysis Block Diagram
  • FIG. 16 is the EDMIS Expert Decision Making Interactive System Block Diagram
  • FIG. 17 is the ADM Alzheimer's Diagnostic Module Block Diagram
  • FIG. 18 is the DBLM Diseased Brain Localization Module Block Diagram
  • FIG. 19 illustrates an enhanced version of the stimulator of Embodiment C.
  • FIG. 20 illustrates a schematic illustration of the gyroscope stabilization and feedback system of the integrative neuro-cognitive system of the present invention.
  • the present invention provides methods and systems configured to identify and treat various medical conditions associated with the neural system.
  • the present invention also provides methods and systems for enhancing cognitive functions in individuals.
  • the present invention provides systems and apparatus configured to identify and treat various brain-related conditions and/or to assess and modify (for example, enhance) at least one of cognitive, behavioral, or affective function or skill in individuals.
  • the system may include at least one stimulator.
  • a suitable stimulator includes, but is not limited to, a first stimulator, which may include at least one of invasive and non-invasive brain stimulation devices, and a second stimulator which is operatively connected to the first stimulator.
  • the first stimulator is configured to stimulate at least one brain region associated with a brain- related condition by employing at least one of electrical, magnetic, electromagnetic, and photoelectric stimuli.
  • the second stimulator is configured to modify at least one cognitive function associated with the identified brain region.
  • the first and second stimulators may form a single integrated device or, alternatively, may form separate parts of the device.
  • the first and second stimulators are configured to operate simultaneously or sequentially.
  • the present invention also provides methods of diagnosing and treating various brain-related conditions and/or of modifying at least one cognitive, behavioral, or affective function or skill in individuals.
  • the method of diagnosing and treating a brain-related condition or for enhancing a cognitive function may include the steps of: (i) identifying at least a brain region associated with the brain-related condition or the cognitive function; (ii) stimulating the brain region by employing a stimulus such as electrical, magnetic, electromagnetic, and photoelectric stimuli; (iii) optionally, stimulating at least one cognitive feature associated with the brain region of at least step (i); (iv) optionally, subjecting the brain region of at least step (i) to a treatment involving at least one of cell replacement therapy, cell regenerative therapy and cell growth; and (v) optionally, subjecting the brain region of at least step (i) to a pharmacological treatment.
  • the present invention provides integrative neuro-cognitive systems for diagnosing and treating various brain-related diseases, and/or for assessing and enhancing particular cognitive, behavioral, or affective functions (or skills) in brain-related cognitive functions in normal individuals (based on an individual-based comparison of structural or functional or cognitive functioning with corresponding statistical health or brain diseases norms or with statistical norms for cognitively enhanced functions).
  • the integrative neuro- cognitive system of the present invention also provides subsequent neuronal electrical or electromagnetic stimulation, and convergent cognitive stimulation of the identified diseased brain regions in an individual or sub-enhanced cognitive function or functions of brain regions,
  • the invention also provides neurodiagnostic computational systems and methodology for differentially diagnosing an individual with a particular brain-related disease or diseases, along with a specification of the individual's particular functional, structural, or cognitive abnormalities.
  • the invention provides neurodiagnostic computational systems and methodology for identifying those particular cognitive function or functions, which may be further enhanced in an individual relative to cognitively enhanced standards for brain functions.
  • the invention also provides apparatus and methods of computing a precise individual-based brain stimulation, and corresponding cognitive stimulation parameters, needed to stimulate the identified disease-related brain loci, or to enhance an identified cognitive skill or function.
  • the invention further provides apparatus and methods for stimulating the relevant brain regions and corresponding cognitive functions, while continuously monitoring and adjusting the brain and cognitive stimulation parameters for a given individual or a disease or a particular cognitive enhancement function, based on a comparison of pre- and post- stimulation neurodiagnostic measurements of the relevant brain function, structure, and corresponding cognitive functions.
  • the invention provides methodology and system for precisely locating and stimulating electrically or electromagnetically the relevant diseased brain regions or regions whose stimulation may improve cognitive performance in a particular skill or skills in normal individuals.
  • the electrical or electromagnetic stimulation may be combined with convergent cognitive stimulation of the same brain regions, and/or with in-vivo regenerative or neuronal implantation of neuroplasticity methodologies which trigger a regeneration, replacement, or growth of the same brain regions stimulated electrically or electromagnetically or cognitively, to maximize the potential therapeutic or neuroplasticity effect, or with any pharmaceutical agent or material which may facilitate the neuroplasticity or regenerative or enhancement of cognitive functions associated with the same brain region or regions being stimulated electromagnetically or cognitively etc.
  • the present invention also describes a computerized statistical assessment methodology and systems for differentiating between individuals with enhanced cognitive function or functions and normal individuals.
  • Figures 1-8 illustrate various structural elements of system 200 of the present invention configured to diagnose and treat medical conditions associated with the neural system, and/or to enhance cognitive functions in mammals.
  • Figure 1 illustrates INDIVIDUAL BRAIN REGIONS 100 that are pathological functional or structural brain features, or cognitive performance features in an individual, which are associated with a specific brain-related disease that is identified by a NEURODIAGNOSTICS MODULE 101 ( Figure 1).
  • NEURODIAGNOSTICS MODULE 101 measures the functional activation or structural maps, or corresponding cognitive performance in an individual for a particular task (or tasks) or during a resting period.
  • NEURODIAGNOSTICS MODULE 101 transfers this information to REGIONS OF rNTEREST COMPUTATIONAL MODULE 102, which identifies those particular brain regions in an individual whose structure, function, or cognitive functions are deviant from their corresponding statistically-established health norms, or from their corresponding statistical norms for cognitively enhanced performance in a particular task.
  • REGIONS OF INTEREST COMPUTATIONAL MODULE 102 outputs these identified statistically-deviant or cognitively-enhanced brain regions in a given individual for analysis in a BRAIN TRAIT COMPUTATION MODULE 103.
  • the BRAIN TRAIT COMPUTATION MODULE 103 determines whether or not any of these identified brain regions statistically fits within known structural, functional, or cognitive pathophysiology of a particular brain-related disease.
  • BRAIN TRAIT COMPUTATION MODULE 103 determines whether or not any of these identified brain regions statistically fits within established norms for enhanced or excellent cognitive or behavioral performance (in a particular task or skill or skills).
  • the COMPUTATIONAL MODULE 102 then outputs these regions to the BRAIN TRAIT COMPUTATION MODULE 103, to determine whether or not any of these identified brain regions statistically fits within known structural, functional, or cognitive pathophysiology of Autism Spectrum Disorder (ASD).
  • ASSD Autism Spectrum Disorder
  • Alzheimer's disease or any other memory loss that is due to aging, dementia or mild cognitive impairment (MCI)
  • MCI mild cognitive impairment
  • statistically established norms indicate that such memory impairment is associated with decreased structure and function of the hippocampus and other medial temporal structures, as well as decreased connectivity between frontal and posterior brain regions and facial recognition regions, or structural, functional, or cognitive impairment of the cerebellum (associated with impaired motor coordination and semantic memory or verbal capability loss), or impairment of mood and executive functioning regions (such as the left prefrontal region and cingulate gyrus and frontal lobe).
  • these brain regions are output to the BRAIN TRAIT COMPUTATION MODULE 103, to determine whether or not any of these identified brain regions statistically fits within known structural, functional, or cognitive pathophysiology of Alzheimer's, MCI, dementia, or age-related memory loss, or other aging illnesses.
  • the TREATMENT MODULE 104 computes the precise individual-based brain and cognitive stimulation parameters needed to stimulate the identified INDIVIDUAL BRAIN REGIONS 100 that are necessary to improve the functional, structural or cognitive disease indices, or to enhance performance in a particular task or tasks.
  • the REGIONS OF INTEREST COMPUTATIONAL MODULE 102 also outputs identified cognitively enhanced brain regions in a given individual for analysis in the BRAIN TRAIT COMPUTATION MODULE 103, to determine whether or not any of these identified brain regions statistically deviates from the established norms for enhanced or excellent cognitive or behavioral performance (in a particular task or skill or skills).
  • the TREATMENT MODULE 104 computes the precise individual- based brain and cognitive stimulation parameters needed in order to improve the functional, structural or cognitive geared towards enhancing performance in a particular task or tasks.
  • the STIMULATION MODULE 105 receives input from the TREATMENT MODULE 104 regarding an individual-based brain and cognitive stimulation including their integrated neuro-cognitive stimulation parameters. Additionally and/or optionally, an IN- VIVO STIMULATOR 109 may be combined with the STIMULATION MODULE 105. In an exemplary embodiment, IN-VIVO STIMULATOR 109 may include in-vivo transplantation or regenerative or stem-cell insertion of neuronal cells or tissue or supportive cells targeting the same INDIVIDUAL BRAIN REGIONS 100.
  • a feedback may be also combined with the STIMULATION MODULE 105, and following the STIMULATION MODULE 105.
  • the feedback may include a post-stimulation measurement carried out by the NEURODI AGNOSTICS MODULE 101 which then undergoes all the sequential computational steps including: the REGIONS OF INTEREST COMPUTATIONAL MODULE 102, the BRAIN TRAIT COMPUTATION MODULE 103, the TREATMENT MODULE 104, and the STIMULATION MODULE 105.
  • All feedback computational steps are aimed towards monitoring and adjusting the individual-based brain and corresponding cognitive stimulation parameters continuously, based on the potential improvement in functional, structural, or corresponding cognitive stimulation in an individual following the administration of brain stimulation and corresponding cognitive stimulation (e.g., until a certain pathophysiological disease threshold has been transcended indicating clinical improvement in that individual or, alternatively, until a certain cognitive enhancement threshold has been transcended indicating an enhancement of a particular cognitive function or functions in an individual).
  • each of the components of Figure 1 i.e., the NEURODIAGNOSTICS MODULE 101, the REGIONS OF INTEREST COMPUTATIONAL MODULE 102, the BRAIN TRAIT COMPUTATION MODULE 103, the TREATMENT MODULE 104, and the STIMULATION MODULE 105) can function independently or separately, or in any possible combination with each other.
  • the NEURODIAGNOSTICS MODULE 101 is configured to translate functional or structural neuroimaging data into statistically valid individual functional activation patterns and statistically valid individual structural maps.
  • the NEURODIAGNOSTICS MODULE 101 is also configured to compare individual cognitive performance data with statistically established health norms.
  • NEURODIAGNOSTICS MODULE 101 is configured to obtain a FUNCTIONAL NEUROIMAGING DATA 1 10, a STRUCTURAL NEUROIMAGING DATA 1 1 1 , and a COGNITIVE DATA 1 12, that are then fed into a STATISTICAL COMPUTATION MODULE 1 14.
  • STATISTICAL COMPUTATION MODULE 1 14 is configured to compute an INDIVIDUAL FUNCTIONAL ACTIVATION DATA 1 16, an INDIVIDUAL STRUCTURAL MAPS 1 18, and an INDIVIDUAL COGNITIVE PROFILE 120.
  • the FUNCTIONAL NEUROIMAGING DATA 1 10 includes various neuroimaging measurements of activation across different brain regions of a specific individual, during the performance of a particular cognitive or behavioral task. Another possible measurement of the FUNCTIONAL NEUROIMAGING DATA 1 10 includes neuroimaging measurements of a specific individual while at rest. This data can be obtained through the use of various magnetic resonance imagining (MRI), functional magnetic resonance imagining (fMRI), positron emission tomography (PET), single photon emission computerized tomography (SPECT), electroencephalography (EEG) and event related potentials (ERP) techniques, among many others.
  • MRI magnetic resonance imagining
  • fMRI functional magnetic resonance imagining
  • PET positron emission tomography
  • SPECT single photon emission computerized tomography
  • EEG electroencephalography
  • ERP event related potentials
  • the STRUCTURL NEUROIMAGING DATA 1 10 includes various neuroimaging measurements of an individual's brain structure.
  • a non-limiting example of structural mapping is the MRJ (although, as detailed above, other devices such as PET and SPECT are also capable of generating structural images).
  • the COGNITIVE DATA 1 12 includes measurements of cognitive performance of an individual in a wide range of possible cognitive or behavioral tests, which may include but are not limited to: response times, accuracy, measures of attention, memory, learning, executive function, language, intelligence, personality measures, mood, and self-esteem, among others.
  • the cognitive data may be obtained through computerized, paper and pencil, interviewing, performance tests or other forms of administering the cognitive or behavioral tests.
  • the cognitive data may be obtained via verbal, written, visual or tactile responses which are input into the computer in various forms.
  • the FUNCTIONAL NEUROIMAGING DATA 1 10 the STRUCTURAL IMAGING DATA 1 1 1, and the COGNITIVE DATA 1 12 are input into the STATISTICAL COMPUTATION MODULE 1 14 which compares each of these types of data to statistically established norms, to determine an INDIVIDUAL FUNCTIONAL ACTIVATION DATA 1 16, an INDIVIDUAL STRUCTURAL MAPS 1 18, and an INDIVIDUAL COGNITIVE PROFILE 120.
  • Various computational softwares for performing those computational and analyses are available, such as ICA, SPM and AutoROI, among many others.
  • the INDIVIDUAL FUNCTIONAL ACTIVATION DATA 1 16 provides unique brain activation patterns of an individual performing a specific cognitive or behavioral task, or while resting, relative to a statistically established norm.
  • the INDIVIDUAL STRUCTURAL MAPS 118 provides unique brain structure of an individual,
  • the INDIVIDUAL COGNITIVE PROFILE 120 includes that individual's unique cognitive capabilities, skills or functions.
  • the NEURODIAGNOSTICS MODULE 101 may consist of the FUNCTIONAL NEUROIMAGING DATA 1 10, the STRUCTURAL NEUROIMAGING DATA 11 1, the COGNITIVE DATA 112, together or separately, or in any combination.
  • the STATISTICAL COMPUTATION MODULE 1 14 is a part of the NEURODIAGNOSTICS MODULE 101 in any combination.
  • a constraint imposed on the possible combinations of these components is that, if the FUNCTIONAL NEUROIMAGING DATA 110 inherently exists in the individual, then the INDIVIDUAL FUNCTIONAL ACTIVATION DATA 1 16 must exist; if the STRUCTURAL NEUROIMAGING DATA 1 1 1 inherently exists in the individual, then the INDIVIDUAL STRUCTURAL MAPS 1 18 must exist; and, if the COGNITIVE DATA 1 12 inherently exists in the individual, then the INDIVIDUAL COGNITIVE PROFILE 120 must exist.
  • FIG. 3 is a simplified illustration of the REGIONS OF INTEREST COMPUTATION MODULE 102 of system 200 of Figure 1.
  • the REGIONS OF INTEREST COMPUTATION MODULE 102 is configured to identify a disease-specific and individual-specific pathophysiological brain regions.
  • the REGIONS OF INTEREST COMPUTATION MODULE 102 is configured to identify the particular functional or structural brain loci, or corresponding cognitive characteristics, that are different in a given normal individual from their corresponding attributes in statistical standard of excellence or enhanced performance in a particular cognitive skill or function associated with a particular brain region.
  • the STANDARD BRAIN REGIONS DEVIATION ANALYSIS 122 is configured to determine which brain regions exhibit a deviation from a statistical established norm for functional activation patterns, brain structure, and cognitive features of a particular excellent or enhanced cognitive or behavioral performance that is output as the REGIONS OF INTEREST DATA 124.
  • Each of the three INDIVIDUAL FUNCTIONAL ACTIVATION DATA 1 16, INDIVIDUAL STRUCTURAL MAPS 1 18, and INDIVIDUAL COGNITIVE PROFILE 120 can function independently or separately, or in any possible combination with the other two modules.
  • the STANDARD BRAIN REGIONS DEVIATION ANALYSIS 122 relies on statistical computation which compares an individual's functional activation patterns to statistically established health norms (which may rely on known standards of normal brain activation during the performance of a particular cognitive or behavioral task or tasks or at rest, or it may rely on a statistical comparison of the individual to a sufficiently large sample of functional activation patterns in a group of normal matched controls performing a particular cognitive-behavioral task or tasks).
  • the comparison of the individual's functional activation patterns, brain structure, or cognitive performance to statistically established health norms relies on a statistical contrast between the individual's cognitive performance values (pixel by pixel, or region by region, functional and structural, or particular brain regions) with the corresponding values of a normally distributed healthy control group or population.
  • the goal of any one of a variety of statistical procedures known in the art is to determine the likelihood of the individual's functional, structural or cognitive values (parsed by cell, region, brain structure, lobe or hemisphere levels) as belonging to the normal distribution of corresponding functional, structural, or cognitive values in normal controls.
  • Different confidence intervals, significance thresholds, and means of reducing error rate etc. can be utilized to determine those regions of interest which are different in the individual relative to the control group.
  • the STANDARD BRAIN REGIONS DEVIATION ANALYSIS 122 may rely on statistical computation which compares an individual's functional activation patterns to statistically established norms for excellent or enhanced particular cognitive, or behavioral performance, in above-average individuals, or following enhancing brain stimulation of the regions corresponding to a particular cognitive function, or enhancing cognitive training of the same particular cognitive function or skill.
  • the comparison of the individual's functional activation patterns, brain structure or cognitive performance to statistically-established norms of functional, structural, or cognitive performance in individuals who exhibit excellent cognitive performance in a particular task or skill can rely on a statistical contrast of the individual's pixel by pixel, or region by region, functional and structural or cognitive performance values with the corresponding values of a normally-distributed healthy control group or population.
  • the goal of any one of a variety of statistical procedures known in the art is to determine the likelihood of the individual's functional, structural, or cognitive values (parsed by cell, region, brain structure, lobe or hemisphere levels) as belonging to the (normal) distribution of corresponding functional, structural, or cognitive values in excellent or enhanced cognitive performance in a particular task or skill from individual normal controls, or following a cognitive training of that particular function, or through enhancing that cognitive function through stimulation of the corresponding brain regions.
  • the STANDARD BRAIN REGIONS DEVIATION ANALYSIS 122 outputs the REGIONS OF INTEREST DATA 124, the particular structural brain loci, functional brain regions, and cognitive features that are deviant from the statistically established functional or structural brain norms.
  • the STANDARD BRAIN REGIONS DEVIATION ANALYSIS 122 outputs the REGIONS OF INTEREST DATA 124 that may includes the particular structural brain loci, functional brain regions, and cognitive features that are different from the statistically established functional or structural brain norms for a standard of a particular excellent or enhanced cognitive performance.
  • autism spectrum disorder structural abnormalities are evidenced by reversed functional activation of right hemisphere RH instead of left hemisphere LH language regions activation patterns in ASD children (and adults) relative to normal matched controls, e.g., hypoactivation of LH's Broca's, Wernicke's regions but hyperactivation of these contralateral regions in the RH in the ASD relative to matched controls.
  • functional hypoactivation of the Amygdala, fusiform gyrus, and dysfunction of inter- hemispheric connectivity measures may occur.
  • a generalized RH dysfunction in the ASD individuals relative to controls which may manifest as a generalized RH hyperactivation in Theory of Mind paradigms, at resting conditions or in language paradigms, may occur,
  • FIG. 4 depicts the BRAIN TRAIT COMPUTATION MODULE 103 of system 200 of Figure 1.
  • BRAIN TRAIT COMPUTATION MODULE 103 is configured to determine whether or not the identified REGIONS OF INTEREST DATA 124 signify a likelihood of the individual being afflicted by a specific functional, structural, or corresponding cognitive impairment related to a specific brain-related disease.
  • the BRAIN TRAIT COMPUTATION MODULE 103 of Figure 1 is configured to determine whether or not the identified REGIONS OF INTEREST DATA 124 signify the likelihood of an individual being below enhanced or excellent functional, structural, or corresponding cognitive-task performance criteria (e.g., in terms of functional, structural, or cognitive values relative to their corresponding values in a sample of individuals with excelled performance).
  • the REGIONS OF INTEREST DATA 124 (which are those brain regions for which the functional activation, structure, or corresponding cognitive performance has been determined to be statically different in an individual than in the control group or, alternatively, relative to a sample of cognitively enhanced performance) is input into the BRAIN TRAIT THRESHOLD COMPUTATION 126.
  • the BRAIN TRAIT THRESHOLD COMPUTATION 126 determines which of these REGIONS OF INTEREST DATA 124 has a functional activation, or structural properties, or corresponding cognitive performance values that are different from disease-specific statistical threshold values that have a high predictive value for the existence of a specific disease in an individual at the time of testing or prospectively at different time points.
  • the REGIONS OF INTEREST DATA 124 is input into the BRAIN TRAIT THRESHOLD COMPUTATION 126 which determines whether these REGIONS OF INTEREST DATA 124 have functional activation or structural values that are the same as, or different from, the statistically determined functional or structural values threshold for a particularly enhanced cognitive function or functions.
  • the BRAIN TRAIT THRESHOLD COMPUTATION 126 determines that the REGIONS OF INTEREST (ROI) DATA 124 are same as, or exceed, the threshold for functional or structural values of a particular region or regions that have been determined as characterizing a particular disease, then it will output an ROI THRESHOLD DATA 128 and a BRAIN CONDITION DATA 129.
  • ROI REGIONS OF INTEREST
  • the BRAIN TRAIT THRESHOLD COMPUTATION 126 will output the ROI THRESHOLD DATA 128 as consisting of all the REGIONS OF INTEREST DATA 124 that are below-threshold regions for a particular brain- related disease specified by the BRAIN CONDITION DATA 129.
  • the BRAIN TRAIT THRESHOLD COMPUTATION 126 In those cases in which the BRAIN TRAIT THRESHOLD COMPUTATION 126 detects statistically significant functional, structural, or corresponding cognitive performance values in an individual that exceed the disease-specific threshold values or, alternatively, are below the disease-specific threshold in cases in which the functional, structural, or corresponding cognitive performance values have been determined to be statistically below those of normal controls, the BRAIN TRAIT THRESHOLD COMPUTATION 126 will also output a BRAIN CONDITION DATA 129 with a specification of what particular brain-related disease is statistically reliably associated with these above-threshold (or below-threshold as explained above) functional, structural, or corresponding cognitive performance values in a given individual.
  • the BRAIN TRAIT THRESHOLD COMPUTATION 126 will output a NO DIFFERENCE DATA 130 (e.g., indicating that no functional, structural, or cognitive patterns exist in the individual that are different from the statistical distribution of normal individuals).
  • the NO DIFFERENCE DATA 130 instigates a TERMINATE TREATMENT AND REPORT NORMAL FINDINGS 131, which terminates the diagnostic phase of the invention with an output to the individual, or the treating clinician, that the individual is not likely to suffer from any brain-related disease and, therefore, no treatment is warranted.
  • the BRAIN TRAIT THRESHOLD COMPUTATION 126 determines that the REGIONS OF INTEREST DATA 124 are same as, or exceed, the threshold for functional or structural values of a particular region or regions that have been determined as characterizing an enhanced performance or function in a particular cognitive task or skill, then it will output an ROI THRESHOLD DATA 128 and a BRAIN CONDITION DATA 129.
  • the BRAIN TRAIT THRESHOLD COMPUTATION 126 will output the ROI THRESHOLD DATA 128 consisting of all the REGIONS OF INTEREST DATA 124 that are below-threshold regions.
  • the BRAIN TRAIT THRESHOLD COMPUTATION 126 detects statistically significant functional or structural values in an individual that exceed the cognitively enhanced threshold values or, alternatively, are below the cognitive enhanced threshold values in cases in which the functional or structural values have been determined to be statistically below those of normal controls
  • the BRAIN TRAIT THRESHOLD COMPUTATION 126 also outputs a BRAIN CONDITION DATA 129 which includes a specification of what particular cognitively enhanced skills or functions are statistically reliably associated with these above-threshold (or below-threshold as explained above) functional, structural, or corresponding cognitive performance values in a given individual.
  • the ROI THRESHOLD DATA 128 includes the identification of all the pixels, or cellular, or regional, or hemispheric brain regions for which the functional, structural, or corresponding cognitive performance levels in an individual have been computed to exceed the disease- specific threshold in an individual or be below the disease-specific threshold (as shown above), and an indication of the precise functional or structural or cognitive values of each of these pixels, or cellular or regional or hemispheric loci relative to their corresponding disease- specific threshold.
  • the ROI THRESHOLD DATA 128 includes the identification of all pixels, or cellular, or regional, or hemispheric brain regions for which the functional, structural, or corresponding cognitive performance levels in an individual have been computed to be lower than the enhanced cognitive performance level in a particular cognitive task or function (or be below the particularly enhanced cognitive threshold as shown above), the ROI THRESHOLD DATA 128 also specifies the precise functional, structural, or cognitive values at each of the identified pixels, cellular or regional or hemispheric loci - along with their corresponding statistically computed thresholds.
  • the BRAIN TRAIT THRESHOLD COMPUTATION 126 outputs a NO DIFFERENCE DATA 130 (e.g., indicating that no functional, structural, or cognitive patterns exist in the individual that are different from the statistical distribution of normal individuals).
  • the NO DIFFERENCE DATA 130 instigates a TERMINATE TREATMENT AND REPORT NORMAL FINDINGS 131 , which terminates the diagnostic phase of the invention with an output to the individual or the treating clinician that the individual is not likely to suffer from any brain-related disease and, therefore, that no treatment is warranted.
  • the BRAIN TRAIT THRESHOLD COMPUTATION 126 outputs a NO DIFFERENCE DATA 130 (e.g., indicating that no functional, structural, or cognitive patterns exist in the individual that are different from the statistical distribution of cognitively enhanced functional or structural features).
  • the NO DIFFERENCE DATA 130 instigates a TERMINATE TREATMENT AND REPORT NORMAL FINDINGS 131 , which terminates the diagnostic phase of the invention with an output to the individual or the treating clinician that the individual is not likely to benefit from any cognitive enhancement treatment.
  • the computation carried out by the BRAIN TRAIT THRESHOLD COMPUTATION 126 is based upon a statistical comparison of an individual's functional activation, brain structure, or cognitive performance with a statistical distribution of the corresponding functional, structural, or cognitive performance in particular brain-related diseases.
  • the computation carried out by the BRAIN TRAIT THRESHOLD COMPUTATION 126 may be based upon a statistical comparison of an individual's functional activation, brain structure, or cognitive performance with a statistical distribution of the corresponding functional, structural, or cognitive performance for particularly enhanced cognitive skills or functions.
  • These statistical comparisons consist of a pixel by pixel, cellular, regional, or hemispheric comparison of that individual's REGIONS OF INTEREST DATA 124 with its corresponding statistical norms for specific diseases or, alternatively, for particularly enhanced cognitive functions.
  • These statistical norms for normal functional, structural, or corresponding cognitive performance may be obtained through meta-analysis (or other statistical procedures) for averaging scientifically published data quantifying functional, structural, or corresponding cognitive performance levels at different pixel, cellular, regional or hemispheric levels, and across different neuroimaging paradigms in a specific disease and a particular sub-phenotype or stage of the specific disease.
  • these statistically computed norms for normal brain functioning, structure, and corresponding cognitive performance may be obtained through a sufficiently large sample of normal vs. diseased individuals for a specific disease, with subsequent statistical methods being utilized to normalize the distribution of normal controls vs. diseased individuals which would result in the computation of a specific statistical threshold for each pixel, cell, region or hemisphere - above or below which values in an individual are likely to represent a specific disease, sub-phenotype or stage of a particular disease.
  • these statistically computed norms for normal brain functioning, structure and corresponding cognitive performance can be obtained through a sufficiently large sample size of normal vs.
  • enhanced cognitive skill or skills performance individuals for a specific skill with subsequent statistical methods being utilized to normalize the distribution of normal controls vs. enhanced cognitive performance individuals which would result in the computation of a specific statistical threshold for each pixel, cell, region or hemisphere - above or below which values in an individual are likely to represent a specific enhanced cognitive performance or skill or skills.
  • varying the significance level, confidence interval, power of test, effect size or other statistical measures which quantify the difference between a particular brain diseased population and normal control population based on a sample from these populations - may allow one to obtain different statistical (predictive) thresholds for distinguishing a brain- related disease from normal control values.
  • the BRAIN TRAIT THRESHOLD COMPUTATION 126 determination of the statistical threshold above- or below- which functional, structural, or corresponding cognitive performance levels are likely to represent a particular brain disease, sub-phenotype, or disease-stage depends upon the analysis of the normal vs. diseased sample distribution (i.e., in those cases in which the statistical analysis has demonstrated that the normal sample yields statistically reliable higher functional or structural values for a particular pixel, cell, region, or hemisphere than the disease sample, then the BRAIN TRAIT THRESHOLD COMPUTATION 126 will determine that values in an individual for that particular pixel, cell, region hemisphere etc.
  • the BRAIN TRAIT THRESHOLD COMPUTATION 126 will determine that an individual who exhibits functional activation, structural volume, or cognitive values for those particular brain regions which are below the computed threshold for the corresponding normal population values will be marked as a diseased region for autism, in that particular individual.
  • the normal sample yields statistically reliable higher functional activation, structural volume, or cognitive values for the hippocampus, medial temporal structures, connectivity between frontal and posterior or facial recognition or cerebellum or cingulated values than for an Alzheimer's or MCI or demented or aging sample. Therefore, the BRAIN TRAIT THRESHOLD COMPUTATION 126 will determine that an individual who exhibits functional, structural, or cognitive values for those particular brain regions which are below the computed threshold for the corresponding normal population values will be marked as a diseased region for Alzheimer's or MCI or aging diseases.
  • the BRAIN TRAIT THRESHOLD COMPUTATION 126 will determine that values in an individual for that particular pixel, cell, region hemisphere etc. which are above the computed threshold for normal population values will be marked as a diseased region for a particular disease.
  • statistical analyses have shown that the normal sample yields statistically reliable lower functional activation, or structural volume values for the RH's contralateral Broca's or Wernicke's regions than in a sample of autistic children.
  • the BRAFN TRAIT THRESHOLD COMPUTATION 126 will determine that values in an individual for the RH's contralateral Broca's or Wernicke's regions that are above the corresponding computed threshold for normal population values will be marked as a diseased region for autism spectrum disorder.
  • a statistical comparison of normal vs. enhanced samples or populations will be performed for pixel by pixel, cellular, regional or hemispheric functional, structural or corresponding cognitive measures.
  • the BRAIN TRAIT THRESHOLD COMPUTATION 126 will determine that values in an individual for that particular pixel, cell, region hemisphere etc. which are below the computed threshold for the enhanced population or sample will de determined as indicating that these cellular, regional, or hemispheric regions are indicative of sub-enhanced functional, structural, or corresponding cognitive performance levels in that particular individual. As such, an excitatory stimulation of these identified sub-enhanced brain regions in an individual may enhance their corresponding cognitive performance.
  • the BRAIN TRAIT THRESHOLD COMPUTATION 126 will determine that values that are above the enhanced sample or population's threshold in an individual may indicate a sub- enhanced functional, structural, or corresponding cognitive level in an individual for a particular cognitive trait, performance or skill. As such, inhibitory stimulation of these identified sub-enhanced brain regions in an individual may enhance their corresponding cognitive performance.
  • the BRAIN TRAIT THRESHOLD COMPUTATION 126 determines whether or not the functional, structural, or corresponding cognitive performance levels in an individual are statistically the "same” or "different” in a given individual relative to their corresponding values in a normal population. Once the BRAIN TRAIT THRESHOLD COMPUTATION 126 has determined that particular REGIONS OF INTEREST DATA 124 do exceed the disease-specific statistical threshold or, alternatively, are below a particular enhanced performance threshold, then it outputs the BRAIN TRAIT DATA 127, which indicates which brain regions are abnormal functionally, structurally, or in terms of their association with particularly impaired cognitive performance, or alternatively which brain regions may be stimulated neuronally or cognitively to enhance a particular cognitive function or skill.
  • the BRAIN TRAIT THRESHOLD COMPUTATION 126 also outputs the BRAIN THRESHOLD DATA 128, which includes a pixel by pixel, cellular, brain region, or hemispheric values and cognitive performance thresholds for normal brain functioning or, alternatively, for enhanced brain functioning along with various statistical indices associated with these computational thresholds such as significance level, confidence intervals etc., or any other statistical measure that assesses the statistical difference between the REGIONS OF INTEREST DATA 124 functional, structural, or cognitive values and the statistically- established threshold for normal brain functioning.
  • BRAIN TRAIT THRESHOLD COMPUTATION 126 determines that all of the REGIONS OF INTEREST DATA 124 do not exceed the disease-specific statistical threshold or, alternatively, are not below the particular enhanced cognitive performance threshold, then BRAIN TRAIT THRESHOLD COMPUTATION 126 outputs a NO DIFFERENCE DATA 129, which then leads to a TERMINATE TREATMENT AND REPORT NORMAL FINDINGS 130 (which terminates the operation of the medical device and notifies the patient or clinician that the individual is normal with no apparent brain-related disease or, alternatively, performs excellent a particular cognitive task and, therefore, cannot benefit from brain and cognitive stimulation geared towards enhancing particular cognitive skills).
  • FIG. 5 illustrates the TREATMENT MODULE 104 of the system 200 of Figure 1.
  • the TREATMENT MODULE 104 is configured to determine the precise brain stimulation, cognitive stimulation, and neuro- cognitive stimulation parameters for an individual with a specific brain-related disease.
  • the TREATMENT MODULE 104 is capable of determining the precise brain stimulation, cognitive stimulation and neuro-cognitive stimulation parameters for a normal individual to enhance a particular cognitive function.
  • the TREATMENT MODULE 104 includes the ROI THRESHOLD DATA 128 and the BRAIN CONDITION DATA 129 of Figure 4, which are input into a TRAIT- THRESHOLD INVERSE STIMULATION COMPUTATION 132 that includes a BRAIN STIMULATION ANALYZER 133, a COGNITIVE STIMULATION ANALYZER 134, and a NEURO-COGNITIVE STIMULATION ANALYZER 136, which in turn produce a corresponding BRAIN STIMULATION DATA 138, a COGNITIVE STIMULATION DATA 140, and a NEURO-COGNITIVE STIMULATION DATA 140.
  • the TRAIT-THRESHOLD INVERSE STIMULATION COMPUTATION 132 is configured to compare between the ROI THRESHOLD DATA 128 functional, structural, or cognitive performance levels that are above or below disease-specific thresholds, or are above or below enhanced cognitive performance levels in an individual and their corresponding functional, structural, or corresponding cognitive performance thresholds, and the BRAIN CONDITION DATA 129, to determine the optimal brain, cognitive, or neuro-cognitive stimulation parameters.
  • a key computational principle guiding the function of the TRAIT-THRESHOLD INVERSE STIMULATION COMPUTATION 132 is that, to improve the functional, structural, or corresponding cognitive performance level in an individual suffering from a particular brain-related disease or, alternatively, to enhance the functional, structural, or corresponding cognitive performance level in a normal individual, it is necessary to stimulate the particularly identified ROI THRESHOLD DATA 128 regions in the inverse excitatory or inhibitory stimulation direction relative to the below or above threshold levels in a given individual.
  • the TRAIT-THRESHOLD INVERSE STIMULATION COMPUTATION 132 will compute a generally excitatory brain or cognitive stimulation.
  • the TRAIT-THRESHOLD INVERSE STIMULATION COMPUTATION 132 will compute a generally excitatory brain or cognitive stimulation of these brain regions.
  • the TRAIT-THRESHOLD INVERSE STIMULATION COMPUTATION 132 will compute a generally excitatory brain or cognitive stimulation of these brain regions.
  • the TRAIT-THRESHOLD INVERSE STIMULATION COMPUTATION 132 will compute a generally inhibitory brain or cognitive stimulation.
  • the TRAIT- THRESHOLD INVERSE STIMULATION COMPUTATION 132 will compute a generally excitatory brain or cognitive stimulation of these brain regions.
  • the same trait-threshold inverse stimulation principle also applies to the TRAIT- THRESHOLD INVERSE STIMULATION COMPUTATION 132 for cognitive enhancement. Specifically, in those cases in which an individual's functional, structural or corresponding cognitive performance levels are below the enhanced-cognitive performance threshold, then the TRAIT-THRESHOLD INVERSE STIMULATION COMPUTATION 132 will compute a generally excitatory brain or cognitive stimulation. Conversely, in those cases in which an individual's functional, structural or corresponding cognitive performance levels are above the cognitive-enhancement threshold, then the TRAIT-THRESHOLD INVERSE STIMULATION COMPUTATION 132 will compute a generally inhibitory brain or cognitive stimulation.
  • the trait-threshold inverse stimulation principle also applies to the TRAIT-THRESHOLD INVERSE STIMULATION COMPUTATION 132 for cognitive enhancement, namely: in those cases in which an individual's functional, structural or corresponding cognitive performance levels are below the enhanced-cognitive performance threshold, then the TRAIT-THRESHOLD INVERSE STIMULATION COMPUTATION 132 will compute a generally excitatory brain or cognitive stimulation. Conversely, in those cases in which an individual's functional, structural or corresponding cognitive performance levels are above the cognitive-enhancement threshold then the TRAIT-THRESHOLD INVERSE STIMULATION COMPUTATION 132 will compute a generally inhibitory brain or cognitive stimulation.
  • the BRAIN STIMULATION ANALYZER 133 compares between ROI THRESHOLD DATA 128 functional levels that are above or below disease-specific thresholds, or are above or below particular cognitive enhancement thresholds, in a given individual and their corresponding functional threshold, while taking into consideration the BRAIN CONDITION DATA 129 particular brain-related disease, or the particular cognitive enhancement goal - to determine the optimal brain stimulation parameters in a given individual. For example, in cases in which an individual's functional or structural activation parameters are below the normal threshold in certain ROI THRESHOLD DATA 128 regions, then the BRAIN STIMULATION ANALYZER 133 will output excitatory brain stimulation parameters.
  • the BRAIN STIMULATION ANALYZER 133 will output inhibitory BRAIN STIMULATION DATA 138 parameters.
  • the COGNITIVE STIMULATION ANALYZER 134 compares between ROI THRESHOLD DATA 128 cognitive levels that are above or below disease- specific thresholds, or are above or below particular cognitive enhancement thresholds, in a given individual and their corresponding cognitive thresholds, while taking into consideration the BRAIN CONDITION DATA 129 particular brain-related disease or diseases, or the particular cognitive enhancement goal - to determine the optimal cognitive stimulation parameters in a given individual. For example, in cases in which an individual's cognitive performance level is below the normal threshold for a particular task or function, then the COGNITIVE STIMULATION ANALYZER 133 will output an excitatory cognitive stimulation parameters.
  • COGNITIVE STIMULATION ANALYZER 133 will output inhibitory COGNITIVE STIMULATION DATA 142 parameters (i.e., cognitive stimulation paradigm or training methodology which attempts to inhibit the abnormal (or sub-enhanced) cognitive function either directly or through the training or stimulation of its opposite or complimentary or other cognitive function, which in effect suppresses or diminishes the particular abnormal or sub-enhanced cognitive function).
  • inhibitory COGNITIVE STIMULATION DATA 142 parameters i.e., cognitive stimulation paradigm or training methodology which attempts to inhibit the abnormal (or sub-enhanced) cognitive function either directly or through the training or stimulation of its opposite or complimentary or other cognitive function, which in effect suppresses or diminishes the particular abnormal or sub-enhanced cognitive function).
  • the NEURO-COGNITIVE STIMULATION ANALYZER 136 compares between ROI THRESHOLD DATA 128 functional, structural, or corresponding cognitive performance levels that are above or below disease-specific thresholds, or are above or below particular cognitive enhancement thresholds in a given individual and their corresponding functional threshold, while taking into consideration the BRAIN CONDITION DATA 129 of a particular brain-related disease, or the particular cognitive enhancement goal - in order to determine the optimal brain stimulation parameters in a given individual.
  • the computation is geared towards identifying the optimal neuro-cognitive stimulation parameters (e.g., in terms of the correspondence between stimulating a specific brain region (or regions) in an excitatory or inhibitory manner and its corresponding cognitive stimulation of the same brain region (or regions) in an inhibitory or excitatory manner, the temporal overlap or separation between the neuronal brain stimulation, and cognitive stimulation of the same or different brain regions, etc.).
  • the NEURO-COGNITIVE STIMULATION ANALYZER 136 computes the above-mentioned optimal neuro-cognitive stimulation parameters.
  • the specific intensity, duration, loci, interval, and other parameters of brain stimulation computed by the BRAIN STIMULATION ANALYZER 133 are determined based on the input from the BRAIN CONDITION DATA 129 in conjunction with the above- mentioned trait-threshold inverse stimulation principle (e.g., in cases in which the individual's ROI THRESHOLD DATA 128 functional or structural levels are relatively far from the BRAIN CONDITION DATA 129 disease threshold or cognitive enhancement threshold, then the inhibitory or excitatory stimulation parameters would tend to be of higher intensity, duration, multiple brain loci etc., and vice versa).
  • corresponding brain regions should be stimulated excitatorily, i.e., hippocampus or temporal lobe or cingulated gyrus for memory or learning enhancement, frontal or prefrontal cortex for executive functions, concentration, learning, intelligence; motor cortex or cerebellum for motor functions and coordination, visual cortex for enhancing visual functions, inhibitive amygdale for fear and anxiety reduction with or without left frontal and prefrontal excitatory stimulation; enhancement of self-esteem or mood or well-being- excitatory stimulation of left prefrontal or frontal, or inhibitive stimulation of the right prefrontal gyrus.
  • corresponding cognitive stimulation can be applied, e.g., which improves or enhances the diseased brain related or cognitive function or enhances the desired cognitive function or functions.
  • An exemplary embodiment of the present invention encompasses the TREATMENT MODULE 104's tentative ROI THRESHOLD DATA 128 of particular brain- related diseases such as Alzheimer's and ASD's BRAIN CONDITION DATA 129.
  • the ROI THRESHOLD DATA 128 is expected to include any one of these regions or any combination thereof: abnormally deficient activation of left frontal, left prefrontal, Broca's, Wernicke's, hippocampus and related regions, anterior cingulated, and also motor, medial temporal gyrus, anthreonal gyrus, cerebellum, and a decline in functional connectivity measures between some or all of these regions.
  • Structural abnormalities may also exist as a decrease in these structures' volume or connecting fibers between these neuronal regions.
  • ROI THRESHOLD DATA 128 is expected to include any one of these regions or any combination thereof: reversed functional activation of right hemisphere RH instead of left hemisphere LH language regions activation patterns in ASD children (and adults) relative to normal matched controls (e.g., hypoactivation of LH's Broca's, Wernicke's regions but hyperactivation of these contralateral regions in the RH in the ASD relative to matched controls).
  • normal matched controls e.g., hypoactivation of LH's Broca's, Wernicke's regions but hyperactivation of these contralateral regions in the RH in the ASD relative to matched controls.
  • functional hypoactivation of the Amygdala, fusiform gyrus, and dysfunction of inter- hemispheric connectivity measures may occur.
  • a generalized RH dysfunction in the ASD individuals relative to controls which may manifest as a generalized RH hyperactivation in Theory of Mind paradigms, at resting conditions or in language paradigms, may
  • an exemplary and only illustrative embodiment of the system of the present invention includes BRAIN STIMULATION DATA 138, or COGNITIVE STIMULATION DATA 142, or NEURO-COGNITIVE STIMULATION DATA 140 excitatory stimulation of the left frontal or left prefrontal or Broca's or Wernicke's or hippocampus and related regions or anterior cingulate or motor or medial temporal gyrus, or anthreonal gyrus or cerebellum, or the functional connectivity between some or all of these regions or stimulation of any combination of these regions - in the case of Alzheimer's disease.
  • an exemplary embodiment of the system of the present invention may include BRAIN STIMULATION DATA 138, or COGNITIVE STIMULATION DATA 140, or NEURO-COGNITIVE STIMULATION DATA 140 excitatory stimulation of any one of these regions or any combination thereof: Broca's or Wernicke's regions, or Amygdala or fusiform gyrus or of inter-hemispheric connections.
  • ASD may call for the BRAIN STIMULATION DATA 138, or COGNITIVE STIMULATION DATA 140, or NEURO-COGNITIVE STIMULATION DATA 140 inhibitory stimulation of the contralateral Broca's or Wernicke's RH regions or a generalized inhibitory stimulation of the RH.
  • the corresponding brain regions should be stimulated excitatorily, i.e., hippocampus or temporal lobe or cingulated gyrus for memory or learning enhancement, frontal or prefrontal cortex for executive functions, concentration, learning, intelligence; motor cortex or cerebellum for motor functions and coordination, visual cortex for enhancing visual functions, inhibitive amygdale for fear and anxiety reduction with or without left frontal and prefrontal excitatory stimulation; Enhancement of self-esteem or mood or well-being- excitatory stimulation of left prefrontal or frontal, or inhibitive stimulation of the right prefrontal gyrus.
  • corresponding cognitive stimulation may be applied (e.g., stimulus which improves or enhances the disease brain-related or cognitive function or enhances the desired cognitive function or functions).
  • An important aspect of the TRAIT-THRESHOLD STIMULATION COMPUTATION 132 is the principle of disease-specific or cognitive enhancement specific neuroplasticity computation, which underlies the computation carried out by the NEURO- COGNITIVE STIMULATION ANALYZER 136.
  • This principle embodies the adaptation of various neuro-cognitive stimulation parameters to a specific brain disease, or particular cognitive enhancement protocol, based on the identification of the specific neuroplasticity features that are associated with these particular brain disease or diseases, and cognitive enhancement protocol or protocols.
  • the NEURO-COGNITIVE STIMULATION ANALYZER 136 takes into account the specific BRAIN CONDITION DATA 129 brain disease or cognitive enhancement goal in a particular individual and, based on this information in conjunction with known neuroplasticity information regarding these ROI THRESHOLD DATA 128 and BRAIN CONDITION DATA 129, the ROI THRESHOLD DATA 128 determines the optimal NEURO-COGNITIVE STIMULATION DATA 140.
  • the neuroplasticity stimulation parameters may include, for example, the following: the intensity of the brain and corresponding cognitive stimulation, their duration, onset and termination times, temporal overlap or separation, order and combination of all possible brain stimulation loci and their corresponding cognitive stimulations, among others. These parameters may all be dynamically changed or adjusted based on the post-stimulation NEURODIAGNSOTICS MODULE 100 and REGIONS OF INTEREST COMPUTATIONAL MODULE 102 and BRAIN TRAIT COMPUTATION MODULE 103 and TREATMENT MODULE 105.
  • NEURO-COGNITIVE STIMULATION ANALYZER 136 is the computation of the optimal neuroplasticity stimulation for treating Alzheimer's memory loss or other MCI, dementia, memory loss diseases, or memory enhancement diseases, which may include: excitatory 10-20 Hz TMS stimulation of the hippocampus or other temporal lobe regions or frontal or prefrontal regions or cingulate gyrus in any possible combination, which will be synchronized with memory enhancement or encoding or retrieval or recall or recognition or mnemonic or perceptual or auditory or semantic memory enhancement cognitive training or stimulation methodologies, to obtain the optimal neuroplasticity potential changes related to memory improvement (e.g., based on the computation of the best neuroplsticity parameters that allow for the most learning, encoding memory retrieval or formation pertaining to these particular ROI THRESHOLD DATA 128 and BRAIN CONDITION DATA 129).
  • the determination by the NEURO-COGNITIVE STIMULATION ANALYZER 136 of the optimal neuroplasticity parameters specific for a particular ROI THRESHOLD DATA 128 and BRAIN CONDITION DATA 129 may be derived from prior art findings regarding any particular combination of ROI THRESHOLD DATA 128 and BRAIN CONDITION DATA 129. Alternatively, it can be computed based on the present invention's post-stimulation dynamic feedback loop with the above-mentioned NEURODIAGNOSTICS MODULE 100, REGIONS OF INTEREST COMPUTATIONAL MODULE 102, BRAIN TRAIT COMPUTATION MODULE 103, TREATMENT MODULE 105 and STIMULATION MODULE 105.
  • the latter feedback loop computation can allow computation of the most effective learning curve or NEURO-COGNITIVE STIMULATION DATA 140 for a particular ROI THRESHOLD DATA 128 and BRAIN CONDITION DATA 129 combination, either as monitored and adjusted dynamically in a given individual, or through a statistical meta-analysis or other statistical methodology for analyzing the effectiveness of various neuro-cognitive stimulation parameters for a particular ROI THRESHOLD DATA 128 and BRAIN CONDITION DATA 129 across multiple individuals having the same ROI THRESHOLD DATA 128 and BRAIN CONDITION DATA 129 combination.
  • the NEURO-COGNITIVE STIMULATION ANALYZER 136 (when embedded and integrated within the post-stimulation feedback loop mentioned above) offers an automatic learning potential for optimizing the neuro-cognitive stimulation parameters for any given ROI THRESHOLD DATA 128 and BRAIN CONDITION DATA 129 combination.
  • An important aspect of the present invention is the capacity of the BRAIN TRAIT COMPUTATION MODULE 103 to offer a differential diagnostic statistical tool for screening, evaluating, and diagnosing the existence of a particular brain-related disease in an individual at the time of testing, or to offer a reliable predictive diagnostic tool based on statistically reliable deviation of the REGIONS OF INTEREST 124 from the corresponding functional, structural, or cognitive performance distribution in the normal population or sample.
  • the BRAIN TRAIT COMPUTATIONAL MODULE 103 may be considered as an independent differential diagnostic tool for assessing the likelihood of an individual being afflicted by a particular brain-related disease, at the time of testing, or prospectively, with a certain probability predictive power, (e.g., in conjunction with the present invention's NEURODIAGNOSTICS MODULE 101 , the REGIONS OF INTEREST COMPUTATIONAL MODULE 102, or as constituting an altogether independent differential diagnostic neurobehavioral tool).
  • the REGIONS OF INTEREST COMPUTATIONAL MODULE 102 may include any one of the three INDIVIDUAL FUNCTIONAL ACTIVATION DATA 1 16, INDIVIDUAL STRUCTURAL MAPS 1 18, or INDIVIDUAL COGNITIVE PROFILE in any possible combination or separately - together with the FUNCTIONAL STRUCTURAL COGNITIVE NORM DATA 121
  • the STANDARD BRAIN REGIONS DEVIATION ANALYSIS 122 is capable of outputting the REGIONS OF INTEREST DATA 124 as either the functional, structural, or cognitive statistically significant deviant features of an individual.
  • the BRAIN TRAIT THRESHOLD COMPUTATION 126 is capable of differentially diagnosing the likelihood of an individual being afflicted with a particular brain-related disease based on functional, structural, or cognitive deviant REGIONS OF INTEREST DATA 124 (separately or together, in any possible combination).
  • the BRAIN TRAIT COMPUTATION MODULE 103 is also capable of offering a differential diagnostic tool for assessing the likelihood of an individual either being afflicted with a particular brain disease, at the time of testing, or prospectively, within set periods of time based on the INDIVIDUAL FUNCTIONAL ACTIVATION DATA 1 16, INDIVIDUAL STRUCTURAL MAPS 1 18, or INDIVIDUAL COGNITrVE PROFILE 120 separately or in any combination.
  • the BRAIN TRAIT COMPUTATION MODULE 103 may also function as a separate or independent neurobehavioral differential diagnostic tool that is capable of screening the wide population for any existent or prospective brain- related disease (or alternatively for enhanced cognitive performance capabilities in an individual) based on either a simple COGNITIVE DATA 1 12 (derived from various cognitive or behavioral testing) which is analyzed by the STATISTICAL COMPUTATION MODULE 1 14 and leads to the INDIVIDUAL COGNITIVE PROFILE 120, or based on more extensive FUNCTIONAL NEUROIMAGING 108 and STRUCTURAL NEUROIMAGING DATA 1 1 1 that are analyzed again by the STATISTICAL COMPUTATION MODULE 114 and lead to the INDIVIDUAL FUNCTIONAL ACTIVATION DATA 1 16 and INDIVIDUAL STRUCTURAL MAPS 1 18 and the above-mentioned COGNITIVE DATA 112 (in any possible combination).
  • a simple COGNITIVE DATA 1 12 derived from various cognitive or behavioral testing
  • Another important aspect of the present invention is the capacity of the BRAIN TRAIT COMPUTATION MODULE 103 to offer a predictive statistical tool for screening, evaluating and diagnosing the probability of an individual being gifted in a particular skill or skills or alternatively, diagnosing or assessing the possibility of enhancing a particular cognitive function or functions in an individual, which is computed based on a statistical comparison of the REGIONS OF INTEREST 124 with the corresponding functional structural or cognitive performance distribution in the normal population or sample.
  • the BRAIN TRAIT COMPUTATIONAL MODULE 103 can be considered as an independent differential diagnostic tool for assessing the likelihood of an individual being afflicted with a particular brain related disease or diseases at the time of testing or prospectively with a certain probability predictive power, e.g., in conjunction with the current invention's NEURODIAGNOSTICS MODULE 101, the REGIONS OF INTEREST COMPUTATIONAL MODULE 102, or as constituting an altogether independent differential diagnostic neurobehavioral tool.
  • the STANDARD BRAIN REGIONS DEVIATION ANALYSIS 122 is capable of outputting the REGIONS OF INTEREST DATA 124 as either the functional or structural or cognitive statistically significant deviant features of an individual from cognitively enhanced statistical norms.
  • the BRAIN TRAIT THRESHOLD COMPUTATION 126 is capable of differentially diagnosing the likelihood of an individual possessing either enhanced cognitive function or functions or alternatively sub-enhanced cognitive performance in a particular skill or skills based on functional, structural or cognitive deviant REGIONS OF INTEREST DATA 124 (separately or together in any possible combination).
  • the BRAIN TRAIT COMPUTATION MODULE 103 is also capable of offering a differential diagnostic tool for assessing the likelihood of an individual possessing sub-enhanced (or enhance) cognitive functioning in a particular skill or skills based on the INDIVIDUAL FUNCTIONAL ACTIVATION DATA 116, INDIVIDUAL STRUCTURAL MAPS 118, or INDIVIDUAL COGNITIVE PROFILE 120 separately or in any combination.
  • the BRAIN TRAIT COMPUTATION MODULE 103 can also function as a separate or independent neurobehavioral predictive assessment statistical tool that is capable of determining whether an individual possesses enhanced cognitive performance capabilities based on either a simple COGNITIVE DATA 112 (derived from various cognitive or behavioral testing) which is analyzed by the STATISTICAL COMPUTATION MODULE 1 14 and leads to the INDIVIDUAL COGNITIVE PROFILE 120, or based on more extensive FUNCTIONAL NEUROIMAGING 108 and STRUCTURAL NEUROIMAGING DATA 1 10 that are analyzed again by the STATISTICAL COMPUTATION MODULE 1 14 and lead to the INDIVIDUAL FUNCTIONAL ACTIVATION DATA 1 16 and INDIVIDUAL STRUCTURAL MAPS 1 18 and the abovementioned COGNITIVE DATA 1 12 (in any possible combination).
  • a simple COGNITIVE DATA 112 derived from various cognitive or behavioral testing
  • the STATISTICAL COMPUTATION MODULE 1 14 leads to
  • the STIMULATION MODULE 105 is configured to stimulate particular brain regions and their corresponding cognitive stimulation in a given individual.
  • the STIMULATION MODULE 105 includes the BRAIN STIMULATION DATA 138, the COGNITIVE STIMULATION DATA 140, and a NEURO-COGNITIVE STIMULATION DATA 140 of Figure 5, which are input into the NEURO-COGNITIVE STIMULATOR 144.
  • the NEURO-COGNITIVE STIMULATOR 144 includes a BRAIN STIMULATOR 146 and a COGNITIVE STIMULATOR 148.
  • the BRAIN STIMULATION DATA 138 and the NEURO-COGNITIVE STIMULATION DATA 140 are input into the BRAIN STIMULATOR 146, and the NEURO-COGNITIVE STIMULATION DATA 140 and COGNITIVE STIMULATION DATA 142 are input into the COGNITIVE STIMULATOR 148.
  • the BRAIN STIMULATOR 146 and the COGNITIVE STIMULATOR 148 determine the INDIVIDUAL BRAIN REGIONS 100, which is the actual stimulation of the identified brain region or regions, and which includes an inhibitory or excitatory brain and cognitive stimulation according to particular stimulation parameters determined by the TRAIT-THRESHOLD INVERSE STIMULATION COMPUTATION 132.
  • An exemplary embodiment of the NEURO-COGNITIVE STIMULATOR 144 includes an integrated BRAIN STIMULATOR 146 and the COGNITIVE STIMULATOR 148, which can stimulate the same INDIVIDUAL BRAIN REGIONS 100 simultaneously or with time-separation between the brain loci and corresponding cognitive stimulation of these brain loci in any possible order.
  • the NEURO-COGNITIVE STIMULATOR 144 stimulates single or multiple INDIVIDUAL BRAIN REGIONS 100 loci with excitatory or inhibitory brain stimulation parameters including the varying of: the intensity or duration or interval of each of the stimulation brain loci separately or together, while also varying the cognitive "excitatory” or “inhibitory” stimulation of each of these brain loci separately or together (e.g., providing cognitive stimulation or training for each of the stimulated brain regions which corresponds to the excitatory or inhibitory feature of the brain stimulation of a particular loci).
  • an excitatory 10-20 Hz TMS of the left prefrontal cortex aimed at improving or enhancing the mood or well-being of an individual can be coupled with a computerized, auditory, or visual presentation of a Beck-based "positive thinking," or change in self-construct cognitive stimulation or training paradigm, which may be juxtaposed together in any possible order and with any temporal separation between their onset, termination time, and length of stimulation.
  • an excitatory 10-20 Hz TMS stimulation of the cingulate gyrus geared towards improving concentration or focus, or in conjunction with temporal or hippocampal excitatory 10-20 Hz TMS stimulation to improve deficient memory, executive function, or concentration capabilities or enhance them can be coupled with a juxtaposition in any temporal order and length or intensity of excitatory cognitive stimulation or training, which may consist of short term memory cognitive exercises or attention allocation exercises.
  • an inhibitory 1 Hz TMS stimulation of diseased Schizophrenic right hemispheric temporal or parietal associated delusional "visions" or “sounds” may be coupled, in any order and temporal length or intensity, with a cognitive stimulation or training geared towards diminishing the likelihood of occurrence of false-perceptions (e.g., through enhanced perceptual training such as enhancing perceptual cues in perceptual illusion paradigms or other perceptual paradigms or, alternatively, through enhancing accurate perception training or through cognitive stimulation or training in enhancing attention or attentional allocation capabilities, or increasing psychophysical judgment capabilities).
  • individuals who have been characterized as possessing functional, structural, or cognitive abnormalities that are characteristic of autism may be stimulated by the NEURO-COGNITIVE STIMULATOR 144 through a combination of excitatory 10-20Hz TMS stimulation of the LH's Broca's and Wernicke's regions and an inhibitory IHz TMS of the abnormally hyperactivated (or structurally enlarged) contralateral RH's Broca's and Wernickes' language regions, that are coupled with cognitive or behavioral stimulation geared towards enhancing language development, articulation, naming, pointing, or joint attention skills, among others.
  • the NEURO-COGN1T1VE STIMULATOR 144 can also facilitate neuroplasticity changes geared towards improving functional, structural, or corresponding cognitive performance capabilities associated with a particular brain disease or, alternatively, geared towards enhancing a particular cognitive function or functions through an excitatory or inhibitory brain stimulation of single or multiple INDIVIDUAL BRAIN REGIONS 100 brain loci, which is combined with "opposite direction" inhibitory or excitatory cognitive stimulation.
  • the NEURO-COGNITIVE STIMULATOR 144 may enhance a particular cognitive function or functions through an excitatory or inhibitory brain stimulation of single or multiple INDIVIDUAL BRAIN REGIONS 100 brain loci which is combined with apparently "opposite direction" inhibitory or excitatory cognitive stimulation.
  • An example of such "opposite-direction" brain stimulation and cognitive stimulation can be the inhibitory 1 Hz TMS brain stimulation of the Amygdala or fusiform gyrus (which have been shown to be hyperactivated in ASD individuals during facial recognition and social cognition tasks, or during non-social communication paradigms or even at resting conditions) during resting conditions or during the conductance of non-social cognition tasks- which may be coupled with focused social cognition stimulation exercises (before or after the inhibitive TMS stimulation during the resting state or non-social communication tasks).
  • the NEURO-COGNITIVE STIMULATOR 144 may activate the BRAIN STIMULATOR 146 or COGNITIVE STIMULATOR 148 separately, or with opposite excitatory vs.
  • the NEURO-COGNITIVE STIMULATOR 144 is also capable of dynamically adjusting or altering the intensity or interval of brain or cognitive stimulation of single or multiple INDIVIDUAL BRAIN REGIONS 100 brain loci, or the temporal juxtaposition of single or multiple brain stimulation loci and their corresponding cognitive stimulation based on potential changes in the TRAIT-THRESHOLD INVERSE STIMULATION COMPUTATION 132 that can arise as a result of the post-stimulation feedback measurement by the NEURODIAGNOSTICS MODULE 101 and subsequent computations by the REGIONS OF INTEREST COMPUTATIONAL MODULE 102, the BRAIN TRAIT COMPUTATION MODULE 103, and the TREATMENT MODULE 105.
  • the NEURO-COGNITIVE STIMULATOR 144, the BRAIN STIMULATOR 146 and the COGNITIVE STIMULATOR 144 form a single integrated medical device, which is capable of synchronizing the brain stimulation of single or multiple brain INDIVIDUAL BRAIN REGIONS 100 loci together with the cognitive stimulation of the same brain loci, which may be controlled by the TRAIT- THRESHOLD INVERSE STIMULATION COMPUTATION 132 output BRAIN STIMULATION DATA 138, the COGNITIVE STIMULATION DATA 140, and the NEURO-COGNITIVE STIMULATION DATA 140.
  • the NEURO-COGNITIVE STIMULATOR 144 can include at least two separate medical devices of the BRAIN STIMULATOR 146 and the COGNITIVE STIMULATOR 148 that are controlled by the same TRAIT-THRESHOLD INVERSE STIMULATION COMPUTATION 132 through its output of the BRAIN STIMULATION DATA 138, the COGNITIVE STIMULATION DATA 140, and the NEURO-COGNITIVE STIMULATION DATA 140.
  • the COGNITIVE STIMULATOR 148 may be of single or multiple presentation of various sensory modality stimulation such as visual, auditory, and tactile, for example, with various response modalities being used in any possible combination, including but not limited to a keypress response, vocal, written, tactile, or visually guided response with or without a response feedback element (e.g., which provides a feedback as to the accuracy of the subject's response or performance at different time points, or with regards to various segments of the task or tasks at hand).
  • various sensory modality stimulation such as visual, auditory, and tactile
  • response modalities being used in any possible combination, including but not limited to a keypress response, vocal, written, tactile, or visually guided response with or without a response feedback element (e.g., which provides a feedback as to the accuracy of the subject's response or performance at different time points, or with regards to various segments of the task or tasks at hand).
  • the BRAIN STIMULATOR 146 may include a medical device capable of stimulating electromagnetically, electrically, magnetically, and/or photoelectrically, and inhibitorily or excitatorily, a single or multiple INDIVIDUAL BRAIN REGIONS 100 brain pixels, regions, tissues, functional neural units, or hemispheres, which have been deemed as functionally, structurally, or cognitively diseased by the BRAIN TRAIT THRESHOLD COMPUTATION 126 and based on the control of the BRAIN STIMULATION ANALYZER 133 and the direct input of the BRAIN STIMULATION DATA 138.
  • the BRAIN STIMULATOR 146 may be a medical device capable of stimulating electromagnetically, electrically, magnetically, or photoelectrically, a single or multiple brain pixels, regions, tissues, functional neural units or hemispheres, which are functionally or structurally associated with a particular sub-enhanced cognitive function or functions by the BRAIN TRAIT THRESHOLD COMPUTATION 126 and based on the control of the BRAIN STIMULATION ANALYZER 133 and the direct input of the BRAIN STIMULATION DATA 138.
  • the BRAIN STIMULATOR 146 may include a medical device capable of stimulating electromagnetically, electrically, magnetically, and/or photoelectrically, and inhibitorily or excitatorily, a single or multiple brain pixels, regions, tissues, functional neural units, or hemispheres through the convergence of at least two electrical, magnetic, electromagnetic, or photoelectric sources of energy or stimulation, in any possible combination.
  • These single or multiple electrical, magnetic, electromagnetic, or photoelectric sources can be placed at any point on top of the cranium or surface of the scalp, or face or neck, broadly defined or non-invasively within any of the orifices located in the head, e.g., the ears, nose, sinuses, mouth and larynx, eyes.
  • each of these stimulating or receiving electrical, magnetic, electromagnetic, or photoelectric sources is controlled individually or collectively by the NEURO-COGNITIVE STIMULATOR 144 and specifically through the dynamic input from the BRAIN STIMULATION DATA 138.
  • the NEURO-COGNITIVE STIMULATOR 144 controls the NEURO-COGNITIVE STIMULATOR 144 and specifically through the dynamic input from the BRAIN STIMULATION DATA 138.
  • feedback measurements are performed by the NEURODIAGNOSTICS MODULE 101, REGIONS OF INTEREST COMPUTATIONAL MODULE 102, BRAIN TRAIT COMPUTATION MODULE 103, TREATMENT MODULE 104, and STIMULATION MODULE 105, as depicted in Figure 1, and as detailed above.
  • the BRAIN STIMULATOR 146 is configured to stimulate particular single or multiple brain loci based on input from the BRAIN STIMULATION DATA 138 and NEURO-COGNITIVE STIMULATION DATA 140, which outputs to the ELECTRODE MOBILIZATION MODULE 107 information regarding the positioning, loci, axis of stimulation, and direction of the ELECTRODE STIMULATOR 108 for stimulation of single or multiple brain loci.
  • the ELECTRODE MOBILIZATION MODULE 107 receives, in turn, monitoring of the current localization, axis, stimulation direction and brain regions, which are input into the ELECTRODE STIMULATOR 108.
  • the ELECTRODE POSITIONING MODULE 106 continuously assists the ELECTRODE MOBILIZATION MODULE 107 to bring the electrodes (or any other electrical or electromagnetic stimulation device) to a position and axis of stimulation or precise localization of stimulation to the determined single or multiple brain regions INDIVIDUAL BRAIN REGIONS 100.
  • the ELECTRODE STIMULATOR 108 is positioned in such single or multiple brain localizations, which allows for the stimulation of the desired single or multiple INDIVIDUAL BRAIN REGIONS 100 as determined through the continuous interaction between the ELECTRODE MOBILIZATION MODULE 107 and the ELECTRODE POSITIONING MODULE 106, then the ELECTRODE STIMULATOR 108 stimulates the desired INDIVIDUAL BRAIN REGIONS 100.
  • the physical engineering or configuration of the ELECTRODE STIMULATOR 108 may be such that it requires little or no physical mobilization by the ELECTRODE MOBILIZATION MODULE 107, but instead is activated based on the BRAIN STIMULATION DATA 138.
  • An example of such an embodiment includes an ELECTRODE STIMULATOR 108 which comprises numerous multiple electromagnetic, magnetic, electrical, and/or photoelectrical stimulators placed at multiple locations on top of the scalp or within the mouth, nose, eyes, or ear cavities and each controlled by a computer signal which allows for the rotation of their electromagnetic or electrical direction, or axis of stimulation or region or regions which are stimulated by each of them.
  • the ELECTRODE STIMULATOR 108 may be constructed such that it sends and receives electrical, electromagnetic, magnetic and/or photoelectrical signals (or any combination of them) between electrodes.
  • the ELECTRODE STIMULATOR 108 may also comprise magnetic, electric, electromagnetic and/or photoelectric stimulators placed at any of the locations mentioned above, and controlled by a mutual computer, which therefore allows for the convergent or emission or receptive stimulation of any single or multiple points, locus or loci, region or regions, of the brain.
  • the functioning of the BRAIN STIMUL ATOR 146 in terms of its ongoing and continuous stimulation of the desired INDIVIDUAL BRAIN REGIONS 100 may be continuously adjusted to simulate the same or different INDIVIDUAL BRAIN REGIONS 100 based on the above-mentioned described invention and depicted in Figure 1.
  • the BRAIN STIMULATOR 146 can serve as a means for treating various brain-related diseases such as Alzheimer's, depression, autism, and other diseases mentioned above, or can serve as a means for enhancing particular cognitive functions or skills in a normal individual.
  • FIG. 8 details another schematic representation of the BRAIN STIMULATOR 146 of Figure 6.
  • the BRAIN STIMULATOR 146 is in the form of a helmet or similar device 300 (shown schematically in Figure 8 as covering at least part of an individual's head 301) including single or multiple ELECTRODE STIMULATOR 108 which are electrical or electromagnetic stimulating agents capable of stimulating single or multiple brain regions, points, cells, lobes, or hemispheres.
  • the ELECTRODE STIMULATORS 108 are controlled by both the BRAIN STIMULATION DATA 138 and the NEURO-COGNITIVE STIMULATION DATA 142 of Figure 7.
  • Each of the single or multiple ELECTRODE STIMULATOR 108 is also being evaluated by an adjacent or associated ELECTRODE POSITIONING MODULE 106, which can determine the location of each of these ELECTRODE STIMULATORS 108 relative to a person's individual brain structure and their respective regions which can be stimulated by the ELECTRODE STIMULATOR 108 in this position or axis of stimulation.
  • each ELECTRODE STIMULATORS 108 is then utilized along with stimulating-agent specific input from the BRAIN STIMULATION DATA 138, and the NEURO-COGNITIVE STIMULATION DATA 142 is output to the ELECTRODE POSITIONING MODULE 106 to adjust the localization, axis of stimulation or specification of the direction, or regions, cells, lobes, or hemispheres or any specification of a single or multiple brain points or locations by the ELECTRODE MOBILIZATION MODULE 107.
  • the ELECTRODE MOBILIZATION MODULE 107 sends, in turn, feedback to the ELECTRODE POSITIONING MODULE 106, thereby allowing for a continuous adjustment and optimization of the precise localization of each of the ELECTRODE STIMULATOR 108 so that it is capable of stimulating all of the determined single or multiple INDIVIDUAL BRAIN REGIONS 100.
  • each of these ELECTRODE STIMULATORS 108 has been determined by its accompanying ELECTRODE POSITIONING MODULE 106 to be located in the appropriate position so as to stimulate the corresponding single or multiple INDIVIDUAL BRAIN REGIONS 100 based on the corresponding BRAIN STIMULATION DATA 138, and based on the input from the NEURO-COGNITIYE STIMULATION DATA 142, the single or multiple ELECTRODE STIMULATOR 108 begin stimulating the determined INDIVIDUAL BRAIN REGION 100 in conjunction with the COGNITIVE STIMULATOR 148 of Figure 6.
  • the ELECTRODE STIMULATORS 108 of device 300 may be placed over the scalp, head, face, neck, or within the eyes, ears, mouth, or nose cavities or orifices/spaces, and which may be either rotated or mobilized or otherwise change their stimulation direction of different single or multiple brain localizations or regions or points.
  • ELECTRODE STIMULATORS 108 Their convergence or emission and reception by different such ELECTRODE STIMULATORS 108 allow for the stimulation of any three-dimensional point or points, cells, tissue, region, lobe, or hemisphere within an individual's brain and can be individually controlled for each of these ELECTRODE STIMULATORS 108 based on the input from the BRAIN STIMULATION DATA 138 and in conjunction with the NEURO-COGNITIVE STIMULATION DATA 142, to treat any brain-related disease or enhance any cognitive function or functions in an individual.
  • An exemplary embodiment of the BRAIN STIMULATOR 146 includes multiple ELECTRODE STIMULATORS 108 that are placed individually over the teeth of a person, or placed anywhere else within the mouth cavity, throat, ears, nose, eyes and on the surface of the scalp, face, neck in a manner which allows for the ELECTRODE MOBILIZATION MODULE 107 to change, alter, or control the direction of electrical or electromagnetic or any combination of these two types of stimulations of each of these specific ELECTRODE STIMULATORS 108, in a manner that allows for each ELECTRODE STIMULATORS 108 to send, transmit, or receive such stimulation through any single or multiple brain point or points or regions, and wherein the precision of any line or slice or direction or region of stimulation may be made more precise or accurate due to the convergence of stimulation from multiple ELECTRODE STIMULATORS 108 or through an emission and reception of electrical or electromagnetic stimulation by single or multiple such ELECTRODE STIMULATORS 108.
  • the whole brain becomes a field of numerous multiple points, lines, spheres, regions, organs, lobes, cells, or hemispheres of potential stimulation by convergence or by emission and reception of single or multiple such ELECTRODE STIMULATORS 108, which are controlled by the input from the BRAIN STIMULATION DATA 138 and based on the above-mentioned invention.
  • Embodiment A includes the elements as described in the following description and with references to Figure 9-13.
  • Embodiment A can provide a synchronized TMS magnetic stimulus and Cognitive training stimulus to the patient at locations identified by the care provider or algorithmically identified Alzheimer's diseased brain regions.
  • the system may include a computer, a TMS Stimulator (905, 907), a housing unit suitable for a patient, with a TMS coil (904).
  • the computer can include two screens (901 , 908) and keyboards (902, 908), one (908) that allows interaction with the operator (909), and the other (901) supplying cognitive stimuli and commanded by the Executive Control Module (ECM).
  • ECM Executive Control Module
  • the patient (910) can provide feedback to the computer (905) using a keyboard (902).
  • the computer (905) instructs the TMS unit (907) to output a pulse utilizing a connection between the two units (91 1) within a pre-defined time period after the application of TMS stimulation.
  • the patient (910) is seated in a comfortable chair (912).
  • the chair allows for seating in an upright or reclining position.
  • the patient's head may be restrained from motion using a restraint (903) and the housing unit (904) may be secured to the patient using appropriate fastening techniques.
  • the TMS magnetic stimulus is applied to the patient (910) using the housing unit via TMS coil (904),
  • the TMS coil is temperature controlled.
  • the TMS magnetic stimulus units are discussed in more detail below.
  • the computer application (906, 1400) for the system of the exemplary Embodiment A of the present invention can provide the following functions, the details of preferred component modules being separately described herein below.
  • the Executive Control Module is responsible for managing the sequencing and state of the treatment session (1408) and application of stimuli.
  • the ISAT (1505) component of END (1404, 1505) uses sequences of MRI images to identify changes in brain mass or structure over time.
  • the ISAT (1505) component of END (1404, 1505) may also utilize any of the other END alternatives (NDA or ADM) in any combination.
  • the EDMIS module uses cognitive test results, the output from END (1404) and input from the caregiver or offsite personnel, to determine the best stimulation locations and training regime, based on stored scripts (1413).
  • the Cognitive Training Module CSM (1412) applies stimulus to the patient (910) based on dynamically alterable scripts (1413).
  • the Diseased Brain Localization Module (DBLM) (1406) takes the location identified by EDMIS (1405) and correlates the identified location for a specific patient's anatomy and locates the correct stimulation locations based on a brain atlas (1407).
  • the Brain Co-Registration Component (907, 1409) determines the exact coordinates of the location to be stimulated on the patient and indicates and controls the registration between the TMS coil location (904), the applied magnetic pulse and the patient's desired stimulus location.
  • an option to Embodiment A may be tailored towards enhancing cognitive functions in normal individuals, for example, by essentially replacing the EDMIS with an equivalent module which is termed Enhanced Cognitive Functions Decision Making System (ECFDM).
  • ECFDM Enhanced Cognitive Functions Decision Making System
  • This module would similarly identify the specific brain region/s which should be stimulated in order to enhance a particular cognitive function or functions or skill/s. based on the input of the END and Cognitive Testing Module, and which is similarly connected to the Executive Control Module which then coordinates (and synchronizes) between the delivery of electromagnetic and cognitive stimulation to the ECFDM's identified brain region/s or loci which need to be stimulated in order to enhance the particular cognitive runction/s in a normal individual.
  • the EDMIS (1405) -- based on patient's response (902) or based on changes in the patient's brain structure, function, neuroplasticity, or neurophysiology etc. as continuously or intermittently measured by the END - ISAT (1505), NDA (1507) or ADM (1506) — makes determinations based on that response, alerting the operator (909) or modifying the script (1413) as required to optimize cognitive training.
  • a feedback loop measures the patient's functional or structural or neuroplasticity or neurophsyiological state (e.g., in terms of degenerative or post- stimulation regenerative/neuroplasticity changes across time, ISAT; or relative to the normal age, education, or other parameters matching population, NDA; or relative to Alzheimer's diseased or relative to any other brain diseased population) prior to single or multiple sessions of electromagnetic and/or cognitive stimulation and also following such single or multiple treatment sessions.
  • This feedback loop utilizes repeated measurements by the END (ISAT, NDA or ADM) and accordingly the EDMIS adjusts the parameters of brain stimulation locus/loci, intensity, duration, frequency etc. and may also adjust the corresponding Cognitive Stimulation of these electromagneticaily stimulated brain regions.
  • Embodiment B An enhancement to the functionality of the system of Embodiment A is the system of Embodiment B which adds the following functions: the full functionality of the END module, the preferred embodiment of which is described in detail below.
  • the END module utilizes one or more of the following algorithms for determination of stimulus locations: [000135] Inter Subject Across Time (END - ISAT) (1505, 1600).
  • Alzheimer's Diagnostic Module (END - ADM) (1506, 2000).
  • Embodiment B may further add computer control of the magnetic stimulation (1010). This feature may be implemented in a closed-loop method by utilizing the functionality of the Brain Co-Registration.
  • Embodiment C An enhancement to the functionality of the system of Embodiment B is the system of Embodiment C, which adds the following components and functions, including the stimulator illustrated in Figure 19.
  • the stimulator of Figure 19 provides enhanced stimulation of the brain regions by utilizing electrical, electromagnetic, magnetic, or a combination of any or all of these.
  • This stimulation may include multiple coils, surface electrodes, and implanted neuronal electrodes, or a combination of any or all of these, placed around the patient's head and in the cavities of the patient's head invasively or non-invasively (2501), to optimize the intensity of targeting a particular brain region (2505).
  • the stimulator of Figure 19 includes a helmet and or frame (2506) with coil position control and stabilization utilizing positional feedback as well as rate feedback mechanisms such as gyroscopic position sensors and gyroscopic stabilization systems (2501), in order to optimize and control stimulation location precisely and automatically.
  • the gyroscopic components can continuously sense, adjust, mobilize and control the location and vector of each of the magnets or electrodes of the helmet or frame (2506).
  • the stimulator of Figure 19 provides vector magnitude and direction control of the applied magnetic field relative to the patient's head or brain regions by providing feedback to the stimulation controller (2503), and can include cooling and thermal management (1 105).
  • the stimulator of Figure 19 includes adjustment of Stimulation Location and Intensity with tracking to Norm or Other indicator as Feedback.
  • the stimulator of Figure 19 is capable of manual or computer control of the stimulation coils and electrodes (2502, 1 104), positioning actuators, and sensors. Under the Computer Control (1106), the system provides real time feedback for stimulation location and intensity, and provides for correction as required.
  • Magnetic Field control module for controlling the applied magnetic field vector using the stimulator of Figure 19.
  • Gyroscopic Control Module which monitors the feedback of the Inertial sensors and controls the gyroscopic stabilization of the stimulator of Figure 19.
  • the system of Embodiment C described above includes all of the subsystems as described in the embodiments below,
  • the ECM (1408) may be a component of a computer application (1400) that controls the application of excitation stimulus (141 1) and cognitive stimulus (1410).
  • the ECM can: (1) manage gathering stimulation location input data from the DBLM (1406); (2) sequence the application of the TMS applied stimulation and the cognitive stimulation to the patient at location(s) specified by the DBLM (1406); and/or (3) monitor the output of the EDMlS (1405) and DBLM (1406), in order to provide modification to the treatment profile, as determined by EDMIS and DBLM.
  • the ECM can: (4) time the cognitive stimulus (1410) for about 50 to 500 mSec after the excitation stimulus (141 1); (5) provide a trigger output to the TMS unit in order to command application of the applied TMS pulse (1410); and (6) utilize the Brain Co- Registration (1409) module to identify the ideal location of coil (904, 1004 and 1 104) and control and locate TMS stimulus (1410).
  • the ECM (1408) can indicate incorrect placement of the coils, or use computer controlled positioning (1010) to correct the stimulus location and communicate with the CSM (1412) in order to coordinate and control cognitive stimulation to the patient.
  • the END Module (1500) includes a set of algorithms to determine the presence of Alzheimer's disease (AD). These algorithms may be part of a larger application, or a separate diagnostic application which in combination with EDMIS (1405) can be utilized for early or late stage diagnosis of disease.
  • the END Module accepts input in the form of MRI (1503) or FMRI (1502) data, expert diagnosis (1501) or Cognitive Test Results (1504), and outputs diagnostic output for AD differential diagnosis (151 1 , 1607, 1807, 2008).
  • the END module uses one or more the following algorithms for determination of stimulus locations:
  • the ISAT may be implemented as a computer algorithm in an application (1400) and uses Multiple MRI images (1601) acquired over a time period, taking at time intervals to determine brain tissue mass or structural changes indicative of Alzheimer's disease.
  • the ISAT module (1505, 1600) takes the MRI (1601) and performs rotation and scaling to achieve the best correlation between the images.
  • the ISAT module (1505, 1600) also differences the images, as well as differences high pass filtered or edged enhanced images in order to locate structural changes and mass changes in the brain.
  • the ISAT module (1505, 1600) indicates the location of suspected areas of change to the user, allowing the user to input, review, and enter or modify the treatment locations.
  • the ISAT module also reads MRI data from industry standard MRI equipment (1503).
  • the ISAT output (1606) indicates specific brain regions to be stimulated and includes a tracking index for each region, allowing quick determination of degradation or improvement.
  • the NDA (1805) is implemented as a computer algorithm and utilizes MRI (1802) and FMRI (1803) data, or cognitive test results (1801).
  • NDA (1805) compares the following indicators of disease to normative values (1804), derived from analysis of industry accepted norms, or norms developed by the applicant.
  • the NDA normative data (1804) is age-matched to the patient.
  • the NDA (1805) scales, rotates and normalizes the data, for comparison to an internally sorted representation of normal subject structure and mass of the same age (1806).
  • the NDA (1804) uses an algorithm consisting of differencing of data between the applied scaled, rotated and intensity-normalized image, and the reference image, comparing the differenced data to a predetermined threshold, that threshold being determined by comparison of normalized normal patient data, to patient data from diseased brain tissue.
  • the NDA disease determining threshold is a spatial threshold in 3 degrees of space, consisting of a 4-dimensional value.
  • the NDA contains multiple thresholds, based on the type of disease, or the level of disease progress to be identified, These NDA utilize multiple thresholds to calculate a disease progression gradient, marking on the output, the magnitude and direction of disease progression, indicating that calculated index and identified area of the brain to the EDMIS algorithm (1808).
  • the NDA output data may be used on its own, to identify and track disease progress for diagnostic purposes.
  • the NDA module may optionally accept input form cognitive performance measures.
  • the ADM (2005) may be implemented as a computer algorithm.
  • the ADM (2005) indicates the presence of disease at very early stages, ideally about 4 to about 10 years prior to onset.
  • the output of the ADM is the diseased brain regions to be stimulated (2006).
  • the ADM utilizes MRI (2003), FMRI (2004) and cognitive test results data (2002) gathered during FMRI (2004) imaging.
  • the ADM (2005) determines diseased brain regions by analysis against properties associated with Alzheimer's disease or MCI patients (2001).
  • the ADM (2005) scales, rotates and normalizes the data, for comparison to an internally sorted representation of diseased subject structure and mass (2008).
  • the ADM (2005) uses an algorithm consisting of differencing of data between the applied scaled, rotated and intensity normalized image, and the reference image, comparing the differenced data to a predetermined threshold, that threshold being determined by comparison of normalized diseased patient data.
  • the ADM disease determining threshold is a spatial threshold in 3 degrees of space, consisting of a 4-dimensional value.
  • the ADM (2005) contains multiple thresholds, based on the type of disease, or the level of disease progress to be identified. These ADM (2005) utilize multiple thresholds to calculate a disease progression gradient, marking on the output, the magnitude and direction of disease progression, indicating that calculated index and identified area of the brain to the EDMIS algorithm (2007).
  • the ADM (2005) output data may be used on its own, to identify and track disease progress for diagnostic purposes (2008).
  • the ADM norm thresholds is calculated from the ADNl database, external databases, or other AD indicative data (2001).
  • the output of the ADM (2005) is the diseased brain regions (2006) which can be utilized either for diagnosing the disease up to about 4 to about 10 years prior to clinical symptoms, or for therapeutically stimulating these diseased brain regions.
  • DBLM Diseased Brain Localization Module
  • the DBLM (2100) may be implemented as a software module or computer application.
  • the DBLM (2100) identifies the diseased location of the brain based on the brain atlas (2102) and the patient's MRl (2106).
  • the DBLM (2100) allows the user to indicate the location of the brain to be stimulated (2104), by allowing the user to click a computer "mouse" on an image of a representative brain, or on a reconstructed MRI image from the patient.
  • the DBLM (2100) receives input from the EDMIS (2105), to establish treatment locations for a specific patient.
  • the DBLM (2100) interfaces to the TMS Stimulator, placing the stimulus pulse in the proper location.
  • the DBLM uses a registration algorithm (2103) to best fit the output of the brain atlas (2101) to the exact location on the patient, utilizing the MRI data (2106).
  • the DBLM registration algorithm (2103) scales, rotates and normalizes the image, comparing the image to the brain atlas internal image (2102).
  • the DBLM (2100) performs a correlation between the representations, locating an offset index to be used as a correction offset between the stored brain atlas image and the patient's image.
  • the offset, scale and rotation values are used to locate the stimulation point in the patient's data (2104).
  • the DBLM (2100) determines the 3 degrees of space coordinate locations of stimulus points, and outputs those locations to the ECM (1408) for stimulation.
  • the DBLM (2100) interfaces with the ECM to allow sequencing through a set of desired stimulus application location(s).
  • the Brain Atlas (1407) is preferably a component of the DBLM application (1406, 2100).
  • the Brain Atlas (1407) includes a data base of known structural brain regions.
  • the Brain Atlas (1407) contains multiple representations of the brain, indexed by the values dependant on entered patient data, age, size, etc.
  • the Brain Atlas (1407) is referenced by the DBLM (1406, 2100) to establish the ideal stimulus location for a given set of outcomes by the EDMIS (1405).
  • the EDMIS (1900) is a process that includes a software module or computer application and interfaces to internal databases, offsite personnel and/or offsite databases.
  • the EDMIS (1900) utilizes the output of the END (1902), Cognitive Test Results (1903) and input from the user (1901) to make determinations on optimal stimulus location,
  • the EDMIS system (1900) outputs information for diagnostic purposes (1912).
  • the EDMIS system (1900) makes determinations of the areas to be stimulated as well as treatment characteristics based on an expert diagnosis by treatment specialists (1909) and/or expert decision system (1906) using input from END (1902) and or Cognitive testing (1903), as well as trained personnel (1901).
  • the EDMIS (1900) utilizes patient feedback (1908) during or after the treatment session or sessions from the CSM (1412) to reassess the stimulation characteristics and instruct the CSM to modify its operation during the treatment session, by re-analyzing the data.
  • the EDMIS (1900) allows input of results (1909) during treatment (1901), post- treatment, as well as previous output from the system, in order to reassess the patient, making suitable changes to the treatment profile, based on re-analysis by END or re- examination of Cognitive Function (1905).
  • the EDMIS computer application or module includes a user interface (1904).
  • the EDMIS (1900) determines the stimulation type and characteristics to be administered to the patient (1905, 1907).
  • the EDMIS (1900) determines the type of cognitive stimulus to be used during the treatment (1907).
  • the EDMIS (1900) interfaces to the DBLM (1911), in order to locate the exact stimulus location in a specific patient (1906), as determined by the MRI image (2106).
  • the Brain Co-Registry (1409) may be implemented as a software module or computer application.
  • the system may utilize an off-the-shelf Brain Co-Registry Component that implements one or more of the following functions.
  • the Brain Co-Registry (1409) determines the region(s) of the brain to be stimulated or being stimulated by the TMS coil (141 1), during the coil aiming or stimulation process.
  • the Brain Co-Registry (1409) may asses in real-time the registration between the applied magnetic field and the stimulation location and or intensity,
  • the Brain Co-Registry (1409) allows optimization either manually or robotically of stimulation location, relative to a pre-identified target region.
  • the Brain Co-Registry (1409) indicates to the user the location of the brain being stimulated, using 3-D image of the brain.
  • the Brain Co-Registry (1409) indicates the relative strength of stimulation using color-coding.
  • CSM Cognitive Stimulation Module
  • the CSM (1412) is a component of Embodiments A-C, and can include a computer application or a component of another application, and can be operated by a script (1413) controlled by the ECM (1408).
  • the CSM Script (1413) can indicate the Cognitive Stimulus (1410) to be applied, the time delay between the applied Magnetic or Electrical Stimulus and the Applied cognitive stimulus (1410).
  • the Script (1413) can include graded responses to patient feedback allowing determination of patient's progress, responses being tagged with scores for determination by the CSM of patient's progress.
  • the CSM (1412) can apply scripted stimuli to the patient monitor, at appropriate intervals, after the ECM (1408) and TMS (1411) have applied the stimuli pulse.
  • the CSM (1412) can accept patient feedback in the forms of answers or responses to the cognitive stimuli, making decision on treatment path in real-time.
  • An exemplary TMS (transcranial magnetic stimulator) (907) suitable for use in embodiments A and B is preferably FDA 510K approved and can be used for clinical trials, as well as deployment to treatment clinics.
  • the TMS stimulator (907) can provide magnetic stimulus to selected regions of the brain, and allow manual placement on the head of the patient being treated (904).
  • An appropriate fastening harness for securing to the patient's head is provided.
  • the location of the TMS stimulator should remain consistent during the treatment interval and should be interfaced to the ECM (905) to allow timing of the applied magnetic pulse to an accuracy of +/- 5 mSec.
  • Suitable stimulation frequencies can be of about 1 to 20 Hz for a period of about 1 to 5 seconds, with pulse envelopes lasting as long as 20 minutes for each cortical region being stimulated.
  • the coil of the TMS Stimulator (907) should not subject the patient to temperature above 40 0 C at any applied point.
  • An exemplary Magnetic Stimulator (2503) for Embodiment C, but also usable with Embodiments A and B, is a plurality of magnetic stimulator coils (for example, 12 coils) adjustably positionable around the patient's head (2501).
  • An integrated system combines multiple magnets and/or electrical emitters, and/or electrical chips and/or associated gyroscopes capable of detecting the precise location and vector of the electromagnetic stimulation of each electromagnetic/electrical stimulators.
  • each electromagnetic/electrical stimulator has associated sensors capable of detecting intensity and vector of each electromagnetic/electrical stimulator, as well as electromagnetic stimulation of other electromagnetic/electrical stimulators - such that the integrated gyroscope-sensor system is capable of identifying or triangulating precise three-dimensional, single or multiple cortical or sub-cortical points in real-time.
  • Additional sensors can be placed at additional positions on the scalp or within intracranial orifices.
  • a cortical or sub-cortical brain registry system allows the extrapolation/computation of the cortical or sub-cortical regions being stimulated when the electromagnetic vector(s) are applied to particular cortical or sub-cortical regions.
  • a system of gyroscopic components and sensors, associated with the magnetic stimulators, can continuously sense, adjust, mobilize and control the location and vector of each of the magnets or electrodes.
  • the gyroscopic-sensor interaction vector triangulation can provide the exact position of the magnetic stimulators, and energy convergence position within a particular brain region can be identified.
  • the intensity of each coil of a respective magnetic stimulator is controllable by the computer (1 107).
  • the Magnetic Stimulator (2503) may include a nose insertable coil, an ear insertable coil, and appropriate coils for the mouth and eyes (2501).
  • the Magnetic Stimulator (2503) modulates the current in the coils (2501) in order to control the exact placement and intensity of the applied magnetic field, as described above, or under the direction of a commercially-available Brain Co-Registry or similar device.
  • Large stimulator coils (2501) are capable of developing about 2 to 3 Tesla at the coils, and about 0.5 to 0.75 Tesla in the cortex at depths of up to about 5 cm.
  • Small magnetic coils are capable of developing about 1.5 to 2 Tesla at the coils, and about 0.1 to 0.5 Tesla at depths up to about 3 to 4 cm.
  • the Magnetic Stimulator control system (2503) of Embodiment C controls the applied slew rate of the magnetic field, and creates magnetic field rise times from about 50 to 2000 uSec.
  • the nose and mouth coils under the direction of the computer (2501) are able to steer and optimize the magnetic field gradient (the intensity) to deep brain areas such as the hippocampus.
  • the stimulator coils (2501) can be mounted in a helmet or similar structure or frame placed on the patient's head (2502).
  • the stimulators of Embodiment C allow stimulation of single or multiple cortical or sub-cortical regions of the brain, by controlling the applied magnetic field vectors. Magnetic stimulation locations can be controlled by the computer by both control of magnetic field gradients, and robotic or inertial movement of the coils in the helmet or frame.
  • the magnetic stimulator of Embodiment C (2503) provides magnetic field optimization through accessory coils located in the orifices of the head (2504, 2501), allowing the field to reach locations deeper and more precisely. Where appropriate, the coils can be temperature controlled.
  • the magnetic stimulator of embodiment C can be provided with an interface to the ECM (1408) to allow timing of the applied magnetic pulse to an accuracy of +/- 5 mSec, and allow for stimulation frequencies of about 1 to 20 Hz for a period of about 1 to 5 second, and application of pulse envelopes for a duration of up to about 30 minutes for each cortical region being stimulated.
  • the Electrical Stimulator of Embodiment C provides brain stimulation using electrical stimulation applied through a suitably located surface or invasive electrodes (2501) or magnetic or electromagnetic coils, conductors, etc. Electrical Stimulator (2503) provides precise electrode implant location details through a brain atlas derived from an MRI (1403) specific to the patient. The Electrical Stimulator (2503) can provide an interface to the ECM to allow triggered application of pulses to the patient's brain, in conjunction with applied TMS pulses or by itself. The electrical stimulator can allow the use of surface electrodes or subcutaneous electrodes, or electrodes placed and located internally or neuronally in the patient's brain.
  • the Electrical Stimulator (2503) can use a plurality of electrodes (for example, about 20 electrodes), supplying 10 to 100 uA stimulus pulses, controlled by the ECM (1408). Pulses can have a frequency of about 1 to 20 Hz, a pulse width of about 0.5 mSec to about 10 mSec and envelope duration of between about 10 to 200 mSec.
  • the Electrical Stimulator (2503) should control the current applied to the stimulation electrodes, in order to place the current gradient maxima at the desired stimulation location.
  • FIG 20 schematically illustrates an exemplary embodiment of a Gyroscope Stabilization and Feedback System (2700) of the integrative neuro-cognitive system of the present invention.
  • System (2700) includes gyroscope stabilization (2701), motor (2702) and gyroscope sensor an d feedback controller (2703).
  • System (2700) also includes at least one magnetic stimulation coil (2704) and a mounting frame (2705).

Landscapes

  • Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Veterinary Medicine (AREA)
  • Developmental Disabilities (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Social Psychology (AREA)
  • Neurosurgery (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Magnetic Treatment Devices (AREA)
  • Electrotherapy Devices (AREA)
  • Radiation-Therapy Devices (AREA)

Abstract

L'invention concerne des systèmes et des méthodes de diagnostic et de traitement de divers états pathologiques cérébraux, et/ou de modification d'au moins une fonction ou compétence cognitive, comportementale ou affective chez les individus. La méthode de diagnostic et de traitement d'un état pathologique cérébral consiste (i) à identifier au moins une région cérébrale associée à l'état pathologique cérébral; (ii) à stimuler la région cérébrale par utilisation d'au moins un stimulus électrique, magnétique, électromagnétique ou photoélectrique; (iii) à stimuler éventuellement au moins une caractéristique cognitive associée à la région cérébrale; et (iv) à soumettre éventuellement la région cérébrale à un traitement basé sur au moins une thérapie de remplacement cellulaire, une thérapie de régénération cellulaire ou la croissance cellulaire.
EP08835645A 2007-10-04 2008-10-03 Systèmes et méthodes de traitement d'états pathologiques associés au système nerveux central et destinés à améliorer les fonctions cognitives Ceased EP2207591A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96057407P 2007-10-04 2007-10-04
US12/153,037 US8498708B2 (en) 2004-09-13 2008-05-13 Integrated system and method for treating disease using cognitive-training and brain stimulation and computerized magnetic photo-electric stimulator (CMPES)
PCT/IB2008/002632 WO2009044271A2 (fr) 2007-10-04 2008-10-03 Systèmes et méthodes de traitement d'états pathologiques associés au système nerveux central et destinés à améliorer les fonctions cognitives

Publications (1)

Publication Number Publication Date
EP2207591A2 true EP2207591A2 (fr) 2010-07-21

Family

ID=40404399

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08835645A Ceased EP2207591A2 (fr) 2007-10-04 2008-10-03 Systèmes et méthodes de traitement d'états pathologiques associés au système nerveux central et destinés à améliorer les fonctions cognitives

Country Status (5)

Country Link
EP (1) EP2207591A2 (fr)
JP (1) JP2011517962A (fr)
CN (1) CN101888875A (fr)
IL (1) IL204785A (fr)
WO (1) WO2009044271A2 (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8591392B2 (en) 2009-04-03 2013-11-26 Neuronix Ltd. Method and system for neurological treatment
KR20120000564A (ko) * 2009-04-24 2012-01-02 어드밴스드 브레인 모니터링, 아이엔씨. 적응적 수행 트레이너
CN102770068A (zh) * 2010-01-26 2012-11-07 沙皮恩斯脑部刺激控制有限公司 用于判断生物医学刺激设备的定向的系统和方法
CN103476456B (zh) * 2010-11-05 2017-10-03 斯坦福大学托管董事会 奖赏相关行为的光遗传学控制
CN102019040B (zh) * 2010-11-29 2012-05-16 中国科学院深圳先进技术研究院 生物反馈光电治疗装置
CN103431859B (zh) * 2012-01-10 2014-12-10 西安交通大学 多任务视觉认知中脑负荷测定的实验方法
CN103301571B (zh) * 2012-03-06 2015-07-29 王绍璠 康疗脑神经失序所引发症状的辅助系统
CN109350861B (zh) * 2012-05-31 2022-11-22 弗托法米克斯股份有限公司 用于处理和/或诊断与运动相关的神经疾病的装置
CN102727311B (zh) * 2012-06-27 2015-04-15 深圳市美德医疗电子技术有限公司 一种用于唤醒手术脑功能刺激的装置和设备
EP2881133B1 (fr) * 2012-07-31 2020-11-04 Sony Corporation Dispositif de sortie de contenu
US9886493B2 (en) 2012-09-28 2018-02-06 The Regents Of The University Of California Systems and methods for sensory and cognitive profiling
WO2014059431A2 (fr) 2012-10-12 2014-04-17 The Regents Of The University Of California Configuration et placement spatial de capteurs d'électrode frontaux pour détecter des signaux physiologiques
EP2916721A4 (fr) * 2012-11-10 2016-10-26 Univ California Systèmes et procédés d'évaluation de neuropathologies
US9114246B2 (en) * 2013-03-15 2015-08-25 University Of Rochester Spinal nerve stimulation rings for rehabilitation of patients with spinal trauma and stroke
JP5345256B1 (ja) 2013-03-26 2013-11-20 謙輔 山川 電気的刺激装置
EP3033007B1 (fr) * 2013-08-15 2019-10-23 The Methodist Hospital Appareil pour fournir une stimulation magnétique transcrânienne (smt) à un individu
CN104545904A (zh) * 2013-10-24 2015-04-29 上海市气功研究所 一种认知脑电检测分析方法及其装置
JP6402303B2 (ja) * 2014-02-06 2018-10-10 国立大学法人 東京大学 磁気刺激装置
US9943698B2 (en) * 2014-04-22 2018-04-17 Lockheed Martin Corporation Cognitive enhancement using feedback
CN105879231B (zh) * 2015-01-04 2023-07-14 深圳英智科技有限公司 经颅磁刺激定位帽及其标记方法
WO2016125159A1 (fr) * 2015-02-03 2016-08-11 Nibs Neuroscience Technologies Ltd. Diagnostic précoce, traitement de la maladie d'alzheimer et d'une déficience cognitive légère
US20180008827A1 (en) * 2015-02-03 2018-01-11 Nibs Neuroscience Technologies Ltd. Diagnosis and treatment of chronic pain
DE102015101823A1 (de) 2015-02-09 2016-08-11 Forschungszentrum Jülich GmbH Vorrichtung und Verfahren zur Kalibrierung einer nicht-invasiven mechanisch taktilen und/oder thermischen Neurostimulation
WO2016196635A2 (fr) * 2015-06-01 2016-12-08 Cerevast Medical Inc. Appareils et procédés de neuromodulation
US10850099B2 (en) 2015-10-23 2020-12-01 Hrl Laboratories, Llc Transcranial stimulation system and method to improve cognitive function after traumatic brain injury
TWI548434B (zh) * 2015-12-18 2016-09-11 Taiwan Resonant Waves Res Corp Resonance Frequency Control System for Parkinson 's Central Nervous System Degradation
CN108014420B (zh) * 2016-11-02 2023-11-14 北京脑泰科技发展有限公司 一种可对手柄姿态进行定位的经颅磁刺激仪
JP2020513253A (ja) * 2016-11-10 2020-05-14 ニューロトラック テクノロジーズ，インク． 認識能力の分析のために、画像取得デバイスを人間のユーザーに関連付けるための方法およびシステム
EP3554606A4 (fr) * 2016-12-16 2020-05-13 Elwha Llc Système et procédé d'amélioration de l'apprentissage par modulation neuronale
JP6716682B2 (ja) * 2017-01-16 2020-07-01 ソウル大学校産学協力団Ｓｅｏｕｌ Ｎａｔｉｏｎａｌ Ｕｎｉｖｅｒｓｉｔｙ Ｒ＆Ｄｂ Ｆｏｕｎｄａｔｉｏｎ 脳刺激システム
CN107185113B (zh) * 2017-06-14 2024-01-30 浙江莱恩海思医疗科技有限公司 治疗装置及包括该治疗装置的治疗设备
CN109954225A (zh) * 2017-12-25 2019-07-02 复旦大学 可变形光遗传多点刺激器件
US11013423B2 (en) * 2018-01-12 2021-05-25 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for personalized treatment of neurological conditions using implantable neurostimulators
CN108653914A (zh) * 2018-03-23 2018-10-16 刘振寰 一种自闭症儿童情绪及社交功能康复治疗装置
US11467665B2 (en) 2018-06-14 2022-10-11 Meron Gribetz Virtual user interface system and methods for use thereof
KR102180762B1 (ko) * 2018-08-10 2020-11-19 서울대학교산학협력단 기억력 향상을 위한 뇌 자극 장치 및 방법
KR102280367B1 (ko) * 2019-01-31 2021-07-22 뉴로핏 주식회사 10-20 시스템 기반의 위치 정보 제공 방법, 장치 및 프로그램
KR102185662B1 (ko) * 2019-01-31 2020-12-02 뉴로핏 주식회사 10-20 시스템 기반의 위치 정보 제공 방법
CN110613879B (zh) * 2019-08-20 2021-06-18 湖南文理学院 一种计算机同步学习记忆分析系统及方法
CN111317904B (zh) * 2020-03-14 2022-05-20 佛山市龙生光启科技有限公司 一种用于治疗阿尔兹海默病的治疗装置
KR102505639B1 (ko) * 2020-04-21 2023-03-08 뉴로엔(주) 뇌 자극 장치
CN111973178B (zh) * 2020-08-14 2024-07-05 中国科学院上海微系统与信息技术研究所 一种脑电信号识别系统及方法
KR102316631B1 (ko) * 2020-11-19 2021-10-22 주식회사 포엔 기계학습 모델을 이용한 전자약 처방 시스템 및 그 제어방법
US11794002B2 (en) 2020-12-15 2023-10-24 Industrial Technology Research Institute Neuromodulation probe
US20240050688A1 (en) * 2020-12-18 2024-02-15 Neuroconnect S.R.L. Device, system and method to induce falling asleep
CN113426017A (zh) * 2021-08-03 2021-09-24 苏州景昱医疗器械有限公司 植入式刺激器及刺激系统
KR102610810B1 (ko) * 2021-11-30 2023-12-13 주식회사 포엔 사용자의 생각을 디코딩하는 인공지능 시스템
CN115445091B (zh) * 2022-09-02 2023-10-27 成都市第四人民医院 一种基于经颅磁刺激的毒品成瘾治疗系统

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6066163A (en) * 1996-02-02 2000-05-23 John; Michael Sasha Adaptive brain stimulation method and system
WO2004082624A2 (fr) * 2003-03-17 2004-09-30 Neurohealing Pharmaceuticals, Inc. Neurorehabilitation a base de modafinil d'une fonction neurologique alteree par suite de lesion cerebrale
EP1620166A4 (fr) * 2003-04-24 2013-01-02 Advanced Neuromodulation Sys Systemes et methodes permettant de favoriser et / ou de produire le developpement, la readaptation, la restauration et / ou la recuperation de la fonction visuelle par la stimulation neuronale
US20050123526A1 (en) * 2003-12-01 2005-06-09 Medtronic Inc. Administration of growth factors for neurogenesis and gliagenesis
EP1809369A4 (fr) * 2004-10-18 2010-06-09 Univ Louisiana Tech Foundation Dispositif medicaux pour la detection, la prevention et/ou le traitement de troubles neurologiques, et procedes associes
US7400927B1 (en) * 2005-01-06 2008-07-15 Chester Litvin Method and system for psychological treatment by brain stimulation of the psychologically disordered object

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2009044271A2 *

Also Published As

Publication number Publication date
IL204785A0 (en) 2010-11-30
JP2011517962A (ja) 2011-06-23
CN101888875A (zh) 2010-11-17
WO2009044271A2 (fr) 2009-04-09
IL204785A (en) 2015-05-31
WO2009044271A3 (fr) 2009-06-04

Similar Documents

Publication Publication Date Title
US20090099623A1 (en) Systems and methods for treatment of medical conditions related to the central nervous system and for enhancing cognitive functions
EP2207591A2 (fr) Systèmes et méthodes de traitement d'états pathologiques associés au système nerveux central et destinés à améliorer les fonctions cognitives
US11529515B2 (en) Transcranial stimulation device and method based on electrophysiological testing
US10363420B2 (en) Systems and methods for restoring cognitive function
US8262714B2 (en) Techniques for selecting signal delivery sites and other parameters for treating depression and other neurological disorders, and associated systems and methods
US20190001133A1 (en) Transcranial electrical stimulation device having multipurpose electrodes
KR101749607B1 (ko) 신경정신병학적 장애들의 치료를 위한 시스템, 장치 및 방법
EP3065815B1 (fr) Méthodes, appareils et systèmes de stimulation transcrânienne
US8942813B1 (en) Transcranial stimulation device and method based on electrophysiological testing
US20090105521A1 (en) Systems and methods for assessing and treating medical conditions related to the central nervous system and for enhancing cognitive functions
US8929991B2 (en) Methods for establishing parameters for neural stimulation, including via performance of working memory tasks, and associated kits
US8838247B2 (en) Transcranial stimulation device and method based on electrophysiological testing
US6990377B2 (en) Systems and methods for facilitating and/or effectuating development, rehabilitation, restoration, and/or recovery of visual function through neural stimulation
US20150174418A1 (en) Device and Methods for Noninvasive Neuromodulation Using Targeted Transcranial Electrical Stimulation
US20130204315A1 (en) Systems for and methods of transcranial direct current electrical stimulation
US20070179558A1 (en) Systems and methods for varying electromagnetic and adjunctive neural therapies
US20100210894A1 (en) Transcranial magnetic stimulation (TMS) methods and apparatus
GB2585282A (en) Systems and methods for clinical neuronavigation
US20180008827A1 (en) Diagnosis and treatment of chronic pain
JP2011517962A5 (fr)
KR20220046123A (ko) 시변자기장을 이용한 경두개 자극 치료장치 및 이를 이용한 경두개 자극 치료방법
WO2009044270A2 (fr) Systèmes et procédés permettant d'évaluer et traiter des états médicaux liés au système nerveux central et d'améliorer les fonctions cognitives
US20240325751A1 (en) Computer-implemented method for enabling patient-specific electrostimulation of neuronal tissue and associated devices and software
EP4122529A1 (fr) Procédé mis en uvre par ordinateur permettant l'électrostimulation de tissu neuronal spécifique au patient, dispositifs et logiciels associés
WO2024006939A2 (fr) Systèmes et méthodes pour caractériser une réponse individuelle à une perturbation cérébrale chez des patients atteints de la maladie d'alzheimer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100504

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20130411

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20160114